Bacteroides: the Good, the Bad, and the Nitty-Gritty

Hannah M. Wexler*

*Wadsworth Anaerobe Laboratory, Greater Los Angeles VA Healthcare Systems, and Department of Medicine,
University of California, Los Angeles, California*

* Mailing address: Wadsworth Anaerobe Laboratory, GLAVAHCS
691/151J, 11301 Wilshire Blvd., Los Angeles, CA 90073. Phone: (310)
268-3404. Fax: (310) 268-4458. E-mail: hwexler@ucla.edu.

INTRODUCTION

By a variety of measures, the species *Homo sapiens* is more microbial than human. Microorganisms comprise only a small, albeit significant, percentage of the body weight (between 2 and 5 pounds of live bacteria). However, in terms of cell numbers, we are about 10% human and 90% bacterial (308)! Further, the number of genes in our microbiome may exceed the number of human genes by two orders of magnitude (264, 308), making us genetically 1% human and 99% bacterial! Consequently, bacteria play a major role in bodily functions, including immunity, digestion, and protection against disease (208). Colonization of the human body by microorganisms occurs at the very beginning of human life (208), and many of these organisms become truly indigenous to the host.

The human colon has the largest population of bacteria in the body (in excess of 10^{11} organisms per gram of wet weight), and the majority of these organisms are anaerobes; of these, ~25% are species of *Bacteroides* (226), the bacterial genus that is focus of this review. This review will summarize the current state of knowledge about *Bacteroides* species, the most predominant anaerobes in the gut. The aspects of these organisms that will be covered will include their role as commensal organisms (The Good); their involvement in human disease (The Bad); and information about their physiology, metabolism, and resistance mechanisms as well as a brief overview of clinical characteristics (The Nitty-Gritty).

Bacteroidetes is one of the major lineages of bacteria and arose early during the evolutionary process (233). *Bacteroides* species are anaerobic, bile-resistant, non-spore-forming, gram-negative rods. The taxonomy of *Bacteroides* has undergone major revisions in the last few decades (see "Taxonomy" below), but the genus is now limited to species within the *Bacteroides fragilis* group, which now number >20. Names of species within the *Bacteroides* or *Parabacteroides* group to date are listed in Table 1 (146). Many of these species were isolated as single strains from human feces. The percentages of anaerobic infections that involve particular species of *Bacteroides* are indicated in Fig. 1 and were calculated from the Wadsworth Anaerobe Collection database, including more than 3,000 clinical specimens from which a *Bacteroides* species was isolated. The proportions of the most important species for the most common sites of isolation are indicated in Table 2. The numbers of *B. fragilis* isolates are 10- to 100-fold lower than those of other intestinal *Bacteroides* species, yet *B. fragilis* is the most frequent isolate from clinical specimens and is regarded as the most virulent *Bacteroides* species.

Bacteroides may be passed from mother to child during vaginal birth and thus become part of the human flora in the earliest stages of life (208). The bacteria maintain a complex and generally beneficial relationship with the host when retained in the gut, and their role as commensals has been extensively reviewed (308). A quote in a recent publication captured this attribute: "...with *B. fragilis*, as with real estate, it's location, location, location" (285). When the *Bacteroides* organisms escape the gut, usually resulting from rupture of the

TABLE 1. Species of the genera *Bacteroides* and *Parabacteroides*

Species
Bacteroides
B. acidifaciens
B. caccae
B. coprocola
B. coprosuis
B. eggerthii
B. finegoldii
B. fragilis
B. helcogenes
B. intestinalis
B. massiliensis
B. nordii
B. ovatus
B. thetaiotaomicron
B. vulgatus
B. plebeius
B. uniformis
B. salyersai
B. pyogenes
B. finegoldii
B. goldsteinii
B. dorei
B. johnsonii
Parabacteroides
P. distasonis
P. merdae

gastrointestinal (GI) tract or intestinal surgery, they can cause significant pathology, including abscess formation in multiple body sites (e.g., the abdomen, brain, liver, pelvis, and lungs) as well as bacteremia.

Recent genomic and proteomic advances have greatly facilitated our understanding of the uniquely adaptive nature of *Bacteroides* species. The completion of the sequencing projects for *B. thetaiotaomicron* in 2003 (306) and *B. fragilis* in 2004 to 2005 (54, 138) and subsequent proteomic analyses have vastly added to our understanding of the manner in which these organisms adapt to, and thrive in, the human gut. A few examples are (i) complex systems to sense the nutrient available and tailor nutrient-metabolizing systems accordingly, (ii) multiple pump systems to rid the bacteria of toxic substances, and (iii) the ability to control the environment by interacting with the host immune system so that it controls other (competing) pathogens. We have recently shown that the expression of the various resistance-nodulation-division (RND) pumps of *B. fragilis* depends upon the site of isolation, another indication that the bacterium can tailor its disposal system according to its habitat (198). Additionally, comparisons of sequence analyses of the genomes of these two species suggested important mechanisms to explain the respective niches and characteristics of these organisms.

A few interesting facts that are common to both genomes have been noted. First, there is an unusually low gene content for their genome size, which reflects a large number of proteins containing >1,000 amino acids (308); many of these predicted proteins were assigned putative functions based on homology with known bacterial proteins (~60% in *B. thetaiotaomicron*). Second, in both *B. fragilis* and *B. thetaiotaomicron*, extensive DNA inversions may control expression of a large number of

genes. Third, both species exhibit multiple paralogous groups of genes, i.e., genes that seem to have derived from a common ancestral gene and have since diverged from the parent copy by mutation and selection or drift. The reasons for this seemingly inefficient use of genetic space are not completely clear, but it would seem that *Bacteroides* species are genetic "pack rats" that prefer to have all possibly needed versions of relevant proteins at hand and therefore will not need to rely on unpredictable mutations.

THE GOOD

Bacteroides as Friendly Commensals

A recent review suggested that commensal is too mild a term for the relationship of *Bacteroides* to its human host. The term commensal implies that one partner benefits from the relationship and the other is unaffected. The authors suggested that mutualism is a more apt description, since both the bacteria and the human experience increased fitness as a result of the relationship (8). The intestinal microbiome endows us with many features that we have not had to evolve ourselves, and we provide the organisms with "bed and board."

Appearance in the GI tract. *Bacteroides* species in the neonate appear at approximately 10 days after birth (251). Breast-fed infants do not show appreciable numbers of *Bacteroides* organisms in their stool until after they are weaned; in these newborns, *Bifidobacterium* is the major genus (150). Bacterial interactions with the host intestinal cells are facilitated by the presence of cellular and stromal components, blood, mucins, and neurons in the intestinal mucosal layer (208).

Nutrient sources for intestinal bacteria. Polysaccharides comprise the most abundant biological polymer and, as such, also the most abundant biological food source. Carbohydrate fermentation by *Bacteroides* and other intestinal bacteria results in the production of a pool of volatile fatty acids that are reabsorbed through the large intestine and utilized by the host as an energy source, providing a significant proportion of the host's daily energy requirement (118). Thus, gut flora provide nutrient sources for the host as well. Studies show that germ-free animals lacking a gut flora need 30% more calories to maintain body mass than normal rats (104); the gut bacteria liberate and generate simplified carbohydrates, amino acids, and vitamins. Other organisms in the gut, without the array of sugar utilization enzymes that *Bacteroides* has, can benefit from the presence of *Bacteroides* by using sugars (generated by the glycosylhydrolases) that they would otherwise be unable to use

FIG. 1. Proportions of *Bacteroides* species seen clinically.

(264). For example, *Bifidobacterium longum* has a better system for importing simple sugars than does *B. thetaiotaomicron*, but *B. thetaiotaomicron* can break down a large variety of glycosidic bonds, providing nutrients that *B. longum* can then use. Also, studies with mice indicate that *B. thetaiotaomicron* can redirect its carbohydrate-utilizing capability from dietary to host polysaccharides according to nutrient availability (265). In another study, the adaptation of *B. thetaiotomicron* to utilize different nutrients during the suckling and weaning periods was investigated (27). Transcriptome analysis indicated that *B. thetaiotaomicron* harvested from the ceca of suckling mice has increased expression of enzymes that can utilize host-derived polysaccharides (host glycans, hexoseamines, and sialic acids that are present in mucus and the underlying gut epithelium), as well as enzymes to aid in the catabolism of mono-and oligosaccharides present in mother's milk. After weaning, the repertoire of sugar-digesting metabolic enzymes was expanded so that plant-derived polysaccharides (which would now be present in the gut) could be utilized (27).

Adaptive survival in the GI tract. *Bacteroides* species have a superb ability to utilize the nutrients at hand. In the large intestine, these bacteria utilize simple and complex sugars and polysaccharides for growth (118). At sites of infection, *B. fragilis* may utilize host cell surface glycoproteins and glycolipids as a nutrient source; these may include simple sugars such as galactose and mannose and more complex compounds (e.g., *N*-acetyl-D-glucosamine [NAG]) and *N*-acetylneuraminic acids). Indeed, the largest paralogous group of proteins in *B. thetaiotaomicron* are those involved in oligo- and polysaccharide uptake and degradation (2, 3, 58, 59, 72, 73, 156, 206, 207, 229, 247, 248, 276), capsular biosynthesis, and environmental sensing/signal transduction/DNA mobilization (306). The authors of the *B. thetaiotaomicron* genome sequence publication suggest that these expansions "reveal strategies used by *B. thetaiotaomicron* to survive and to dominate in the densely populated intestinal system" (306). The coupling of these paralogs with a variety of regulatory apparatus may explain the exquisitely tuned ability of *Bacteroides* to sense and adapt to environmental changes and stresses, such as would normally be encountered in the gut. Another system used by *Bacteroides* to adapt to the human gut is its ability to modulate its surface polysaccharides by "flipping" the promoters needed for their expression to an "on" or "off" position (137); this ability may allow it to evade a host immune response.

Carbohydrate metabolism in *B. thetaiotaomicron*. *B. thetaiotaomicron* has an extensive starch utilization system and multiple genes (*sus* genes) that are involved in starch binding and utilization. One hundred seventy-two glycosylhydrolases and 163 homologs of starch binding proteins (106 members homologous to SusC and 57 members homologous to SusD [306, 308]) enable the organisms to use the wide variety of dietary carbohydrates that might be available in the gut. Nearly half of the genes encoding the starch binding proteins (SusC homologs) are located next to glycosylhydrolase genes. In all, *B. thetaiotaomicron* contains more glycosylhydrolases than any sequenced prokaryote and appears to be able to cleave most of the glycosidic bonds found in nature (307). This ability to adapt to the use of different nutrient sources undoubtedly gives it an "edge" in its intestinal environment. These proteins may also

be important in the attachment of the organism to mucus glycans.

Carbohydrate metabolism in *B. fragilis*. The polysaccharide-utilizing ability of *B. fragilis* has not been as extensively studied, although analysis of the proteome of *B. fragilis* and comparison with *B. thetaiotaomicron* also suggests a tremendous capacity to use a wide range of dietary polysaccharides. A few years ago, we characterized a 200-kDa two-component protein (Omp200 [composed of Omp120 and Omp70, corresponding to their respective apparent molecular masses]). The intact two-component system had pore-forming ability in liposomes and black lipid bilayer membranes (two artificial systems that mimic the outer membrane of the cell and can measure pore formation). The 120-kDa component of this porin had significant homology to *B. thetaiotaomicron* SusC proteins (301). While Omp71 had no detectable similarity to SusD, it had homologs in the *B. thetaiotomicron* genome that are positioned next to a SusC homolog. Xu and Gordon speculated that the *B. fragilis* SusC-like component may be a conserved component of multifunctional outer membrane proteins. These multifunctional complexes may be divided into two groups: those with a downstream *susD* homolog that may affect acquisition/utilization of polysaccharides and those with homologs of *omp71*, encoding a protein whose function has not yet been defined (308).

The *B. fragilis* neuraminidase enzyme (product of the *nanH* gene) catalyzes the removal of terminal sialic acid from surface polysaccharides (105), and *nanH* mutants are often growth deficient. Because NAG is used in cell wall production, the ability to use extracytoplasmic NAG facilitates cell growth (181). Possibly, neuraminidase activity may render other carbon sources available when glucose levels are reduced (105), thus serving the nutritional requirements of the bacterium.

Miscellaneous enzymes used in sugar transport or utilization. Many bacteria have transport-linked phosphorylation systems that allow sugars transported into the cells to be immediately utilized in pathways for energy metabolism or biosynthesis; any sugar transported across the cell membrane by these phosphotransfer systems can immediately enter metabolic or biosynthetic pathways. Genes for these systems were not found in the genome of either *B. fragilis* or *B. thetaiotaomicron*. Thus, they must have alternate ways of transporting sugars into the cell and attaching an active phosphate moiety. Recently, two broad-specificity hexokinases from *B. fragilis* were characterized, and their roles in hexose and NAG utilization were studied (31). These enzymes allow utilization of nutrients found in the gut (undigested dietary polysaccharides and host-derived glycoproteins) and at sites of infection (host cell surface antigens [including the Lewis antigen] and glycolipids) (31).

Association of levels of intestinal *Bacteroides* with obesity. During the last 2 years, there have been a number of reports in prominent journals pointing out that the respective levels of the two main intestinal phyla, the *Bacteroidetes* and the *Firmicutes*, are linked to obesity, both in humans and in germfree mice (102, 143, 144, 280). The authors of the studies deduce that carbohydrate metabolism is the important factor. They observe that the microbiota of obese individuals are more heavily enriched with bacteria of the phylum *Firmicutes* and less with *Bacteroidetes*, and they surmise that this bacterial mix

may be more efficient at extracting energy from a given diet than the microbiota of lean individuals (which have the opposite proportions) (280). In some studies, they found that the relative abundance of *Bacteroidetes* increases as obese individuals lose weight and, further, that when the microbiota of obese mice are transferred to germfree mice, these mice gain more fat than a control group that received microbiota from lean mice (280). Until very recently, reports in the literature agreed that *B. thetaiotaomicron* had more glycosylhydrolases than any sequenced prokaryote and appeared to be able to cleave most of the glycosidic bonds found in nature (307). However, the most recent genomic analysis found that environmental gene tags coding for many enzymes involved in the initial steps in breaking down otherwise indigestible dietary polysaccharides were enriched in obese mice (note that these were *ob/ob* homozygous mice with a defective leptin gene as well). The genome of *Eubacterium rectale* (a member of the *Firmicutes* division), which has not been completed, is significantly enriched for glycoside hydrolases compared to several completed genomes of *Bacteroides* species (280).

While it is not completely clear how significant these differences are or how well they will translate into human equivalents (9), they have, in fact, been extended to the human diet. A very recent study found that diets that are based on a high intake of protein but a low intake of fermentable carbohydrate (e.g., many of the popular diets, including Atkins, South Beach, etc.) may alter the gut flora. These workers found that proportions of *Bacteroides* and several clusters of *Clostridia* were not altered but that numbers of *Roseburia*, *Eubacterium rectale*, and bifidobacteria decreased significantly as carbohydrate intake decreased (79). Furthermore, human colonic butyrate-producing organisms that are related to *Roseburia* spp. and *Butyrivibrio fibrisolvens* showed an increased ability to use a variety of starches for growth compared to *B. thetaiotaomicron* (202).

Adaptation of *B. thetaiotomicron* and *B. fragilis* to their respective microenvironments. While both *B. thetaiotaomicron* and *B. fragilis* contain large numbers of paralogous genes, comparison of the two genomes suggests that they are specifically tailored for their respective microenvironments. For example, *B. fragilis* has a pronounced capacity to create variable surface antigenicities by multiple DNA inversion systems (138). This surface-altering capability is more developed in *B. fragilis*, which is more frequently found at the mucosal surface (i.e., often the site of attack by host defenses) than is *B. thetaiotaomicron*. Also, the ability of *B. fragilis* to tolerate and use oxygen may account for the observation that it is found in greatest numbers at the mucosal surface, where the P_{O2} should be higher than it is within the intestinal lumen (13). The impressive capacity to utilize polysaccharides is more pronounced in *B. thetaiotaomicron*, which is more concentrated within the colon. The multiplicity of sensing systems of *B. thetaiotaomicron*, discussed below, also allow fine-tuned and efficient recruitment of the appropriate carbohydrate utilization systems. This was aptly illustrated by a very recent study that demonstrated adaptations in *B. thetaiotomicron* in the guts of mice during the suckling period and after weaning. By analyzing whole-genome transcriptional profiles of the bacterium harvested from the intestines of mice at different time points, the authors demonstrated that in sucking animals, glucose/galac-

tose transporters and other glycosidases (enzymes that would be important in using host glycans sources) were expressed at higher levels, whereas *B. thetaiotaomicron* harvested from mice in the weaned stage showed increased expression of genes for enzymes that can liberate sugars from plant polysaccharides. Thus, during the suckling period, *B. thetaiotomicron* preferentially used host-derived polysaccharides as well as mono-and oligosaccharides present in mother's milk, and after weaning, this organism expanded its metabolism to exploit abundant polysaccharides of plant origin (27).

Environmental Sensing Systems

Beneficial symbiosis requires that the bacteria can sense changes in the environment so that they can adapt to alterations in their surroundings. The genome studies of *B. thetaiotaomicron* reveal that they have multiple genes encoding signal sensing systems; these include σ-factors and two-component regulatory systems. The function of these systems in *Bacteroides* is not understood to the extent that they are understood in aerobic bacteria, but indications are that they serve similar functions.

ECF σ-factors. σ-factors are essential dissociable protein subunits of prokaryotic RNA polymerase that are necessary for initiation of transcription. These factors provide promoter recognition specificity to the polymerase and contribute to DNA strand separation; they then dissociate from the RNA polymerase core. In some cases the factor may regulate large numbers of prokaryotic genes, and in some cases the genes comprising a sigma factor regulon have a clearly defined function (131). One class of these factors, the extracytoplasmic function σ-factors, known as ECF-type σ-factors, are relatively small proteins (65). They are frequently associated with specific membrane-tethered cognates, known as anti-σ-factors. This cognate may receive a signal causing it to release its σ-factor; the released σ-factor can then interact with RNA polymerase to initiate transcription.

B. thetaiotaomicron contains the largest proportion and number of ECF σ-factors among the species of *Bacteria* and *Archaea* for which complete genome data are available (307). Approximately half of the ECF σ-factor genes are located next to open reading frames encoding putative anti-σ-factors. Further, all but one of these ECF σ-factor/anti σ-factor pairs is located upstream of open reading frames encoding homologs of the polysaccharide binding *susC* gene products. While the starch binding proteins are located on the cell surface, the starch-degrading enzymes are located in the periplasm, perhaps to allow *Bacteroides* exclusive access to the substrate (3). However, genomic analysis of *B. thetaiotomicron* identified a host of glycosyl hydrolases (α-galactosidases, β-galactosidases, α-glucosidases, β-glucosidases, β-glucuronidases, β-fructofuranosidases, α-mannosidases, amylases, and endo-1,2-β-xylanases, plus 14 other activities); 61% of these glycosylhydrolases are predicted to be in the periplasm or outer membrane or to be extracellular and may be important in shaping the nutrient availability of the intestinal ecosystem (306). Taken together, these results suggest a finely tuned regulatory system that allows *B. thetaiotaomicron* to sense the nutrients at hand and adjust its metabolism accordingly, thus benefiting (i) itself, (ii) other bacteria that cannot utilize the complex polysaccha-

ride, and (iii) the human host, who obtains 10 to 15% of his/her caloric intake through microbial fermentation of oligosaccharides (307).

Two-component signal transduction systems. The architecture and regulation of two component signal transduction systems have been extensively studied (268). These systems allow organisms to sense and respond to changes in many different environmental conditions. The prototype structure is well conserved and includes a histidine protein kinase that is regulated by environmental stimuli. In response to a stimulus, this protein autophosphorylates at a histidine residue, creating a high-energy phosphoryl group. The phosphoryl group is subsequently transferred to an aspartate residue in the response regulator protein; this induces a conformational change in the regulatory domain that results in activation of an associated downstream domain and causes the response (268). The majority of response regulators are transcription factors with DNA-binding effector domains, although some have C-terminal domains that function as enzymes. Examples of this system include regulation of the differential expression of *ompF* and *ompC* by the EnvZ-OmpR system in *Escherichia coli* and of the commitment to sporulation by the Spo system in *Bacillus subtilis* (268). While there are few functional studies of these systems in *Bacteroides*, it is reasonable to assume that they are similar to those described for other organisms. For example, expression of a two-component regulatory system gene from *Bacteroides* that was cloned into a multicopy plasmid vector in *E. coli* resulted in a decrease in the level of the outer membrane porin protein OmpF and an increase in the level of the outer membrane porin protein OmpC (204).

One *Bacteroides* two-component regulatory system which has been extensively studied is the RteA-RteB two-component system. The tetracycline resistance gene, *tetQ*, is part of the *rteA-rteB-tetQ* operon, which is located on a mobile element (CTnDot [see below]) found in many strains of *Bacteroides*. RteA is the sensor component, and RteB is the transcriptional regulator that controls the expression of a third downstream gene, *rteC*. The RteC product, in turn, controls the expression of a gene cluster (*orf2C*) that is important for excision (and therefore of transfer) of the CTnDot element. Tetracycline has a stimulatory effect on expression of the RteA-RteB system and, therefore, on both expression and transfer of tetracycline resistance. However, the *rteA* gene is not directly sensing tetracycline, and exactly what it is sensing is not yet clear (164).

In addition to the sizeable numbers of classical two-component systems (i.e., sensor kinases and response regulators), there is a family of 32 unique proteins in *B. thetaiotaomicron* that incorporate all of the domains found in the classical two-component system into a single polypeptide. In one system, nutrient sensing is coupled to regulation of monosaccharide metabolism (263). BT3172 belongs to this family of proteins, and its expression is regulated by polysaccharides in the environment. The presence of α-mannosides in the medium can induce expression of BT3172, which, in turn, will cause upregulated expression of secreted α-mannosidases. This system may also be important for capsular polysaccharide gene expression. Typically, expression of one of the capsular polysaccharide synthesis loci (*cps3*) is upregulated when polysaccharides are scarce. In a mutant deficient in BT3172, expression of *cps3* is increased even in the presence of a medium rich in polysac-

charides, suggesting that BT3172 is important for the bacterium to properly interpret its nutrient landscape in terms of adequate supply of polysaccharides (263).

Another feature of the ability of BT3172 to sense the neighboring polysaccharide landscape is that it can modulate "mimicry" so that the surface polysaccharide structure of the bacterium can be altered to match the surrounding landscape, possibly allowing the bacterium to avoid eliciting a host immune response (68).

Cross talk between *Bacteroides* and the intestinal cells. Most of the characteristics of *Bacteroides* discussed to this point pertain to the adaptability of *Bacteroides* to its environment and changes that occur as a result of alterations in that environment. However, this is a two-way communication system, and studies have shown that the intestinal *Bacteroides* strains directly modulate gut function (94). Almost a decade ago, Hooper et al. demonstrated that *B. thetaiotaomicron* can modify intestinal fucosylation in a complex interaction mediated by a fucose repressor gene and a signaling system (121). Subsequently, using transcriptional analysis, they demonstrated that *B. thetaiotaomicron* could modulate expression of a variety of host genes, including those involved in nutrient absorption, mucosal barrier fortification, and production of angiogenic factors (120). The line of communication from bacterium to intestinal cell can morph into a complete circle: *B. thetaiotaomicron* can stimulate production of RegIIIγ, a bactericidal lectin, which can then bind directly to bacterial peptidoglycan in gram-positive bacteria and result in bacterial killing (53).

Interactions with the Immune System

There are numerous studies detailing the host immune response to bacterial virulence factors. However, the vast majority of human-bacterial interactions are benign and commensal or mutualistic in nature. Intestinal bacteria are important in the development of gut-associated lymphoid tissues (GALT): in the absence of bacterial colonization, development of GALT is defective (117). In rabbits, the combination of *B. fragilis* and *Bacillus subtilis* consistently promoted GALT development and led to development of the preimmune antibody repertoire (212). Mazmanian and Kasper reviewed the factors that allow the GI tract—an environment with multiple immune capabilities—to coexist with the huge numbers of bacteria found there (154) and proposed a model whereby the immune capabilities of the GI tract are profoundly affected by some of those bacteria. The general outline of this model is described below.

Polysaccharides produced by *B. fragilis* are important in the activation of the T-cell-dependent immune response. A zwitterionic polysaccharide (ZPS) produced by *B. fragilis* can activate CD4$^+$ T cells (i.e., T helper cells expressing the CD4 [cluster of differentiation 4] glycoprotein). Polysaccharides A and B (PS-A and PS-B) of the *B. fragilis* capsular polysaccharide complex are both ZPSs. Normally, polysaccharides (which almost never carry a positive charge) are considered activators of B cells, and they promote increased immunoglobulin M (IgM) production but without IgG production and without a memory response. However, the unusually structured ZPSs can bind onto the borders of the peptide-binding groove on major histocompatibility com-

plex class II molecules of the antigen-presenting cells (APCs) and dock in this groove, and they can thus be presented to the T-cell receptors of CD4$^+$ T cells in the same way that a peptide or glycopeptide conjugate would be presented. Experimental data indicate that these ZPSs are internalized by the APCs, processed by chemical oxidation into smaller fragments, and then presented to the T cell at the surface of the APC. Indeed, these ZPSs appear to be important in the development of CD4$^+$ T cells. Splenocytes from germfree mice showed a lower proportion of CD4$^+$ cells than splenocytes from conventionally colonized mice, and colonization with *B. fragilis* (even in the absence of all the other gut microflora) could correct this proportion in the germfree animals. Moreover, colonization with a mutant that could not produce PS-A was not able to correct the defect, whereas PS-A alone could also correct the defect (154, 155).

The CD4$^+$ T cells stimulated by PS-A produce interleukin-10 (IL-10), which can act to prevent abscess formation and other inflammatory responses. Also, in either in vivo or in vitro experiments, these PS-A-stimulated cells also produce gamma interferon, IL-2, and IL-12. The studies accomplished by this group reveal an intricate "dance" between the microbe and certain components of the host immune system, and the authors conclude that the PS-A of *B. fragilis* "is necessary and sufficient to mediate the generation of a normal mature immune system" (154).

Gut bacteria and the "hygiene hypothesis." There have been reports that modulation of the immune system by the commensal gut bacteria is important in allergy development. One scenario is that increases in vaccination, antibiotic usage, and disinfectant use decrease the gut flora at an important point in the development of the immune system, which results in a skewing of the immune system toward TH2 cell response and overproduction of TH2 cytokines and IgE; the innate immune mechanisms and TH1, TH2, and regulatory T cells are all part of this fine balancing act (210). The specific bacterial determinants of this phenomenon are not clear. Mazmanian and Kasper suggest that *B. fragilis* PS-A may be involved (154). Others suggest that lipopolysaccharide (LPS) (not necessarily *Bacteroides* LPS), which at low levels is an inducer of IL-12 and gamma interferon (cytokines that stimulate TH1-mediated immunity and decreases the production of TH2 inflammatory cytokines such as IL-4, IL-5, and IL-13), is part of this process (293).

***Bacteroides* can affect expression of Paneth cell proteins.** Small intestinal crypts house stem cells that serve to constantly replenish epithelial cells that die and are lost from the villi. Paneth cells (immune systems cells similar to neutrophils), located adjacent to these stem cells, protect them against microbes by secreting a number of antimicrobial molecules (defensins) into the lumen of the crypt (97), and it is possible that their protective effect even extends to the mature cells that have migrated onto the villi (97). In animal models, *B. thetaiotaomicron* can stimulate production of an antibiotic Paneth cell protein (Ang4) that can kill certain pathogenic organisms (e.g., *Listeria monocytogenes*) (119). In newborn mice, *B. thetaiotaomicron* promotes angiogenesis and postnatal development (266).

Limiting Colonization of the GI Tract by Pathogens

Studies by Wells and colleagues indicate that anaerobic bacteria play a pivotal role in limiting the translocation of normal intestinal bacteria but that other bacterial groups also have a role in preventing the intestinal colonization and translocation of potential pathogens (295). Recent studies suggest that *Bacteroides*, and possibly specific species of *Bacteroides*, have a role in preventing infection with *Clostridium difficile* (122, 123). As detailed above, the development of the immune response that limits entry and proliferation of potential pathogens is profoundly dependent upon *B. fragilis*. Also as mentioned, Paneth cell proteins may produce antibacterial peptides in response to stimulation by *B. thetaiotomicron* (119), and these molecules may prevent pathogens from colonizing the space. In addition, *B. thetaiotomicron* can induce Paneth cells to produce a bactericidal lectin, RegIIIγ, which exerts its antimicrobial effect by binding to the peptidoglycan of gram-positive organisms (53).

TRANSITION: FROM COMMENSAL TO PATHOGEN

As outlined above, *Bacteroides* species are normally commensals in the gut flora. However, these organisms can also be responsible for infections with significant morbidity and mortality. A similar scenario is found with the "commensal gone bad" (186), i.e., *Enterococcus faecalis*. *E. faecalis* is normally a benign resident of the gut flora. However, the first vancomycin-resistant enterococcal strain had a number of DNA elements, apparently of foreign origin, which comprised a quarter of the genome of that strain (186). These elements included a variety of resistance determinants as well as a pathogenicity island carrying a number of virulence-associated genes. Thus, there may be considerable "sharing" of genes within the crowded neighborhood of the gut flora. Acquiring genes that favor the "new" resident (e.g., genes that code for improved adhesion, new nutrition pathways, antibiotic resistance, and inhibition of host defenses) will give these organisms an edge in establishing a niche for themselves. Indeed, some bacteria may not even need to acquire new genes. Organisms such as *Bacteroides* with such a large genome bank at their disposal may simply need to turn on certain genes (such as those involving new nutrition pathways, efflux pumps to rid the cell of toxic substrates, or new surface epitopes) to change from friendly commensal to dangerous threat (104).

Additionally, the capsular polysaccharide of *B. fragilis*, which is so important in development of the host immune system, is also responsible for abscess formation; it is thus one of the most important virulence determinants in this bacterium and is the most obvious bacterial element that is both "friend and foe."

The proportions of various species of the *B. fragilis* group found in anaerobic infections are given in Table 2.

THE BAD

Virulence

Although *B. fragilis* accounts for only 0.5% of the human colonic flora (190), it is the most commonly isolated anaerobic pathogen, due in part to its potent virulence factors. Virulence factors can generally be subdivided into three broad categories:

TABLE 2. Proportions of various species of the *B. fragilis* group found in anaerobic infections[a]

Site/specimen	No. of specimens	% of isolates[a]												
		B. caccae	*B. capillosus*	*B. distasonis*	*B. fragilis*	*B. merdae*	*B. ovatus*	*B. putredinis*	*B. stercoris*	*B. thetaiotaomicron*	*B. uniformis*	*B. vulgatus*	*B. fragilis* group	Total[b]
Abdominal (peritoneal)	713	2.8	0.8	10.0	31.0	0.4	10.9	0.4	1.8	15.4	4.9	9.4	7.0	95.0
Appendix	490	3.5	0.4	10.2	26.7	0.6	11.4	0.6	2.0	16.3	4.5	9.2	11.0	96.5
Blood	286			4.9	61.2		5.2			12.2		5.2	2.4	91.3
Buttock, hip, or groin rectal	195			8.7	35.9		9.2			15.4		10.3	5.1	84.6
Miscellaneous wound ulcer	182				44.0		11.0			14.8		8.2	11.0	89.0
Foot abscess or ulcer	179				41.3		8.9			9.5		5.6	22.3	87.7
Leg	86		2.3	5.8	36.0		4.7			23.3	2.3	7.0	17.4	98.8
Bone	72		8.3	2.8	33.3		12.5			19.4	6.9		12.5	95.8
Bronchial specimen (including TTA)[c]	66		4.5		39.4		3.0			7.6		7.6	31.8	93.9
Chest	63		3.2		11.1					9.5		4.8	61.9	90.5
Above the neck	53		3.8	3.8	22.6		3.8			13.2		5.7	39.6	92.5
Urinary tract infection	21													
Obstetric/ gynecological	19													
Liver	19													
Bile duct	14													
Stump wound	14													
Penis	11													
Brain	8													
Skin	7													
Blind loop	5													
Hand	5													
Oral	4													
Cerebrospinal fluid	3													
Heart	3													
Arm	3													
Hemovac tube	3													
Vertebrae	2													
Prostrate	2													
Lymph	1													
Total	2,529													

[a] Proportions of species were calculated for sites for which >50 specimens were documented.
[b] The isolates enumerated account for >80% of infections.
[c] TTA, transtracheal aspirate.

those involved in (i) adherence to tissues, (ii) protection from the host immune response (such as oxygen toxicity and phagocytosis), or (iii) destruction of tissues. *Bacteroides* strains may possess all of these characteristics. The fimbriae and agglutinins of *B. fragilis* function as adhesins, allowing them to be established in the host tissue. The polysaccharide capsule, LPS, and a variety of enzymes protect it from the host immune response. The capsule is responsible for abscess formation, and histolytic enzymes found in *B. fragilis* can mediate tissue destruction.

The bacterial capsule. The capsule of *B. fragilis* initiates a unique immune response in the host: abscess formation. The actual formation of the abscess is an example of a pathological host response to the invading bacterium: a fibrous membrane localizes invading bacteria and surrounds a mass of cellular debris, dead polymorphonuclear leukocytes, and a mixed population of bacteria (282). Abscesses left untreated can expand and can even cause intestinal obstruction, erosion of resident blood vessels, and ultimately fistula formation. Abscesses may also rupture and result in bacteremia and disseminated infection.

B. fragilis is the only bacterium that has been shown to induce abscess formation as the sole infecting organism. Abscess formation has been clearly linked to the *B. fragilis* capsule in an animal model (282). Injection of capsules alone was sufficient to induce abscess formation (67), while systemic injection prevented abscess formation in rats, presumably due to antibody development and subsequent protection (281). Responses to most other polysaccharide antigens are T-cell independent, but abscess formation induced by *B. fragilis* is dependent on T cells (243–245, 310).

The *B. fragilis* capsule was first analyzed with a prototype strain. Two distinct high-molecular-weight polysaccharides (PS-A and PS-B) that are coexpressed were described (179, 283), and the structures of these two polysaccharides were elucidated (14). PS-A is made up of repeating tetrasaccharide units, and PS-B is made up of repeating hexasaccharide units (283, 289). Other strains of *B. fragilis* were subsequently analyzed, and all possessed a complex capsular polysaccharide composed of at least two different polysaccharides; these polysaccharides were antigenically diverse, although some cross-reactivity with the prototype capsular polysaccharide was seen (180). A third capsular polysaccharide (PS-C) was also found, and the biosynthetic loci involved were cloned and sequenced (67, 129).

The assignment of specific biosynthetic loci (involving up to 22 genes/locus) to specific polysaccharides has been amended since first described (67), but the basic features of the complex polysaccharides remain. The most predominant feature of these polysaccharides is the presence of both positively and negatively charged groups on each repeating unit. The two polysaccharides have very different net charges at physiological pH and exhibit variable expression on the bacterial cell surface (180). The zwitterionic motif is necessary for the activities of this group of molecules, including promoting the formation of abscesses (282). The structural basis of the abscess-modulating activity of the polysaccharide has been extensively studied; one model suggests that grooves in the polysaccharide may serve as "docking sites" for α-helices of specific molecules (e.g., immu-nomodulating molecules such as major histocompatibility/antigen molecular complexes) and thus trigger specific T-cell responses which then lead to abscess formation (289).

There are various opinions concerning the prevalence of capsule among clinical isolates of *B. fragilis* (48, 180, 193); one possible explanation is that different staining techniques will detect capsule to different extents (180). Electron micrographs reveal that even within an individual strain of *B. fragilis*, one might observe a large capsule, a small capsule, and noncapsulate variants. The large capsule and unencapsulated strains share antigenic epitopes, but the bacteria with small capsules are different. Intra- and interstrain antigenic variation was noted (184), and this variation has been observed in clinical isolates from a variety of anatomical sites and different geographical locations and also in bacteria grown in an in vivo model of peritoneal infection (184). Expression of the different capsular types is inheritable, since populations can be enriched for their particular type by subculture from different layers of density gradients. In some bacteria that appear noncapsulate, an additional electron-dense layer might be visible adjacent to the outer membrane.

Evasion of host immune response. The ability to evade the host immune response certainly contributes to the virulence of a bacterium. The *B. fragilis* capsule can mediate resistance to complement-mediated killing and to phagocytic uptake and killing (98, 209, 252). Recent studies indicate that *B. fragilis* may interfere with the peritoneal macrophages, the first host immunologic defense response to rupture of the intestine or other compromise of the peritoneal cavity (287). Macrophages are important for early immune responses to invading microorganisms, and the production of nitric oxide (NO) is central to this function. NO is generated by inducible nitric oxide synthase (iNOS) following exposure to certain cytokines (e.g., gamma interferon). These cytotoxic radicals enhance microbicidal function but can also act on host cells to produce cell necrosis or death. In the study mentioned above, macrophages activated by interaction with *B. fragilis* showed decreased NO production, decreased iNOS activity, and colocalization of iNOS and actin filaments in the macrophage cytoskeleton, along with pore formations not seen in the control cells. The authors concluded that the infection of macrophages with *B. fragilis* leads to actin filaments and iNOS extrusion through the pore formations, thus allowing the bacteria to evade killing by the macrophages.

Another remarkable feature of *Bacteroides* is its ability to modulate its surface polysaccharides. The production of these polysaccharides is regulated by a reversible inversion of the DNA segment containing the promoter needed for their expression to an "on" or "off" position (137). These inversions are mediated by invertase genes; *mpi*, the best known of these genes, codes for a global DNA invertase that is involved in inverting 13 distinct DNA regions, including the promoters of seven of the capsular polysaccharide biosynthesis regions (69). By changing its surface architecture, *Bacteroides* may avoid the host immune response; other potential effects of surface modification would include the ability to colonize host tissue or form biofilms.

Enzymes implicated in virulence. Proteases of *B. fragilis* have been implicated in destroying brush border enzymes (214); these enzymes on the microvillus membranes aid in

the final digestion of food and in mechanisms that provide for the selective absorption of nutrients. The most widespread histolytic enzymes in *B. fragilis* include hyaluronidase and chondroitin sulfatase, which attack the host extracellular matrix (222). Some strains produce other histolytic (e.g., fibrinogenolytic) enzymes (57). Two hemolysins (HlyA and HlyB) have been characterized in *B. fragilis*; these are two-component cytolysins that act together in hemolysis of erythrocytes (216).

Neuraminidase, the product of the *nanH* gene in *Bacteroides* species, cleaves mucin polysaccharides and enhances growth of the bacterium by generating available glucose (105). This enzyme is found in many pathogenic bacteria and is generally considered a virulence factor (223), and many strains of *B. fragilis* produce neuraminidase (22, 274). Neuraminidase can catalyze the removal of the sialic acid from host cell surfaces and from important immunoactive proteins such as IgG and some components of complement and may consequently disrupt important host functions (237).

Enterotoxin. The *B. fragilis* enterotoxin (BFT) is a zinc metalloprotease (136, 162) and may destroy the zonula adherens tight junctions in intestinal epithelium by cleaving E-cadherin (303), resulting in rearrangements of the actin cytoskeleton of the epithelial cells and loss of tight junctions. The result is that this barrier leaks and results in diarrhea (303). More recent evidence indicates that this action is initiated when BFT binds to a specific receptor other than E-cadherin (305). BFT is secreted by enterotoxigenic *B. fragilis* (ETBF) strains, which encode three isotypes of BFT on distinct *bft* loci, carried on a 6-kb genome segment unique to these strains, called the *B. fragilis* pathogenicity island (238).

There is evidence that the enterotoxin pathogenicity island is contained within a novel conjugative transposon (91). This pathogenicity island is flanked by genes encoding mobilization proteins (92) and may thus be transmissible to nontoxigenic strains. A recent study found that 57% of blood culture isolates contained the pathogenicity island and/or its flanking segments (19% had both and 38% had just the flanking segments). Comparatively, in *B. fragilis* isolates from other clinical sources, 10% had both the pathogenicity island and flanking segments, 43% had only the flanking segments, and 47% had neither. The authors deduced that the pathogenicity island and the flanking elements may be general virulence factors of *B. fragilis* (61). BFT also induces cyclooxygenase 2 and fluid secretion in intestinal epithelial cells (133). Finally, BFT has a possible role as a carcinogen in colorectal cancer (277).

The presence of the BFT gene is generally detected by PCR techniques (246). In a study of strains from Germany and from southern California, blood culture isolates were more likely to carry the enterotoxin gene than were other isolates (62). There is some association of ETBF and inflammatory bowel disease (IBD), although rigorous, clear-cut correlation has not been demonstrated (12, 192). While the enterotoxin gene was not found in patients with inactive IBD, 13% of patients with IBD and 19% of patients with active disease were toxin positive. For an exhaustive description of ETBF, see the review by Sears (238).

Endotoxin/LPS. LPS in *B. fragilis* has an unusual structure (291) and is 10 to 1,000 times less toxic than that of *E. coli*. Thus, it is generally not referred to as "endotoxin," although it

does have a demonstrable toxicity (71). The induction of endotoxin liberation on exposure to antibiotics was many times higher with *B. fragilis* than with the other species of the *B. fragilis* group, which may also help to explain why this species is particularly associated with clinical infections and higher mortality (221). Both LPS and capsule may also function as adhesins that allow the bacterium to become established at the site of infection (15).

Aerotolerance of *Bacteroides*. Aerotolerance is not an obvious virulence factor, but it is likely that the ability to survive oxidative stresses plays a role in its ability to initiate or persist in infection (253). Further discussion of the oxidative stress response in *Bacteroides* is found later in this review.

Infections in Adults

Anaerobic infections are usually polymicrobial, and *Bacteroides fragilis* is found in most of these infections, with an associated mortality of more than 19% (107). If a documented *B. fragilis* infection is left untreated, the mortality rate is reported to be about 60% (107). This mortality rate can be greatly improved, however, with use of appropriate antimicrobial therapy (107). Therefore, therapeutic regimens are normally designed to cover this species.

Intra-abdominal sepsis. Intra-abdominal sepsis is the most common infection caused by *Bacteroides*. After disruption of the intestinal wall, rupture of the diverticula, or other perforations due to a surgical wound, malignancies, or appendicitis, members of the normal flora infiltrate the normally sterile peritoneal cavity, and the resultant infections reflect the gut flora composition. During the early, acute stage of infection (approximately 20 h), the aerobes, such as *E. coli*, are the most active members of infection, establishing preliminary tissue destruction and reducing the oxidation-reduction potential of the oxygenated tissue. Once sufficient oxygen has been removed to allow the anaerobic *Bacteroides* species to replicate, these bacteria begin to predominate during the second, chronic stage of infection.

Perforated and gangrenous appendicitis. Detailed bacteriologic studies performed in our laboratory recovered more than 20 genera and 40 species of organisms from specimens taken from patients with gangrenous and perforated appendicitis (21); *B. fragilis* and *E. coli* were the most frequently recovered anaerobic and aerobic species, respectively. *B. thetaiotaomicron* was also frequently recovered (in more than 70% of the specimens). The other species of the *B. fragilis* group were also found but in lower percentages of specimens.

Gynecological infections. *Bacteroides* species are not part of the normal flora of the vagina but are occasionally isolated from vaginal cultures. The rates of vaginal carriage of *Bacteroides* in healthy women (both pregnant and nonpregnant) were estimated to be between 0 and 6% (142, 145), but this rose to 16% in women in labor (141) and to 27 to 28% in patients with cervicitis (145). In a study of 120 pregnant women attending a hospital in Warsaw, Poland, several distinct subgroups of *B. fragilis* were found, including one ETBF strain, which was genetically different than ETBF strains obtained from other sources (142).

Pelvic infections in which *B. fragilis* is likely to be involved are often characterized by the presence of an abscess (175); *B.*

fragilis has been isolated from Bartholin's abscess (an abscess in the glands at the side of the vaginal opening) (45) as well as abscesses in the ovaries or fallopian tubes (23). In a large study assessing risk factors for intrauterine growth retardation, colonization of the cervix and/or vagina with *Bacteroides*, *Porphyromonas*, and *Prevotella* was significantly associated with intrauterine growth retardation (100). In a study of 39 women with mild to severe pelvic inflammatory disease, *B. thetaiotaomicron* was recovered from the endometria or Fallopian tubes of several women with moderate to severe pelvic inflammatory disease (116).

Skin and soft tissue infections. Necrotizing soft tissue infections are typically polymicrobic. In one retrospective study of 196 patients, nearly half had mixed aerobic and anaerobic growth, and *Bacteroides* species were the most common organisms isolated (84). In our studies, *Bacteroides* was not the most common anaerobic organism isolated; nevertheless, 7% of the anaerobes belonged to the *B. fragilis* group (299). In general, the organisms found in soft tissue infections reflect the normal flora found in the adjacent region. A comprehensive study of the bacteriology of human bite wounds (which include clenched fist injuries) included multiple anaerobes, basically reflecting the oral flora (e.g., *Prevotella*, *Fusobacterium*, and *Peptostreptococcus*); *Bacteroides* was not reported in these specimens (158). In a study of infected dog and cat bites, 56% of specimens (50 dog bites and 57 cat bites) yielded both aerobes and anaerobes. *B. fragilis* was isolated from one patient with a dog bite and from one patient with a cat bite, and *B. ovatus* was isolated from one patient with a dog bite (272).

Endocarditis and pericarditis. Involvement of anaerobic bacteria in endocarditis is unusual (26), but when it does occur it may have serious consequences (including valvular destruction, dysrhythmias, and cardiogenic shock), with a mortality rate of 21 to 43% (42). The predominant anaerobes in pericarditis are the *B. fragilis* group and probably occur from hematogenous spread (40). If *B. fragilis* is found, the most likely source is the GI tract; a literature review of endocarditis due to anaerobes reported 53 cases, and a variety of sources of the infecting organism, including a GI malignancy, liver abscess, ruptured appendix, and decubitus ulcer (26).

Bacteremia. The incidence of anaerobic bacteremia decreased in the 1980s but has been steadily increasing since the early 1990s. At the Mayo Clinic, 91 cases/year during 2001 to 2004 were seen (a 74% increase over that in the 1980s) (139). Increasing numbers of compromised and/or elderly patients may be one reason for this increase; also, improved survival rates among cancer patients may be another reason: chemotherapy may cause damage of GI mucosal barriers, allowing anaerobic bacteria to pass through and ultimately enter the bloodstream (139).

In one study of *Bacteroides* bacteremia, 44% of 128 patients had a surgical procedure within 4 weeks of the bacteremia and 30% had a malignancy (169). Twenty-eight percent of the patients had a polymicrobial bacteremia, and nine of the patients were infected with two different *Bacteroides* species. The mortality rate for all patients was 16% if active therapy was instituted and 45% if inappropriate therapy was given. In another study, bacteremia occurred in 27% of patients with necrotizing soft tissue infections; *Bacteroides* isolates were the most common species recovered (84). In this study, the presence of bacteremia was the only microbiological variable known to affect mortality. In a medical center setting in Taiwan, 48% of the systemic infections could be traced to a GI source, and 27% of patients with community-acquired anaerobic bacteria had an underlying malignancy. Strains of the *Bacteroides fragilis* group species were the most common anaerobic isolates, occurring in 45% of the cases (124).

According to a review by Brook, the mortality rate for *Bacteroides* bacteremia is up to 50% and is somewhat dependent on the species recovered (*B. thetaiotaomicron* > *B. distasonis* > *B. fragilis*); whether this is due to differences in virulence factors or to differences in antimicrobial susceptibility is not known (44).

Septic arthritis. *Bacteroides fragilis* is a rare cause of septic arthritis. Most patients with *B. fragilis* septic arthritis have a chronic joint disease, particularly rheumatoid arthritis, and sources of infection include lesions of the GI tract and the skin (1, 29, 76, 112, 157, 220, 309). There is one report of a case of hip septic arthritis in an alcoholic patient (157). In that paper, the authors reported that about 9% of cases of anaerobic septic arthritis are attributed to *B. fragilis*, but the references for these data were two decades old, and the taxonomic changes that have occurred since then would render that data misleading. A 2006 report reviewed cases of infection in prosthetic joints and did find reports of infection with anaerobes, including *Clostridium difficile*, *Clostridium perfringens*, *Porphyromonas melaninogenica*, and *Veilonella* species, but not *Bacteroides* species (151). However, one recent report of an improved method of culturing these infections found one isolate of *B. fragilis* in intraoperative specimens from 72 patients with prosthetic joint revision (a total of 155 isolates were recovered) (239).

Brain abscess and meningitis. While not common, cases of meningitis due to *B. fragilis* have been reported (4, 88, 93, 163, 168, 172, 183). If these organisms are isolated, a predisposing source of infection should be sought (168). Ventriculoperitoneal shunts that perforate the gut may lead to a shunt infection with *Bacteroides* and ultimately to meningitis (50).

IBD. ETBF has been implicated in IBD, but the correlation is not straightforward (12). In one study, the rate of ETBF was high in patients with or without disease. The prevalence of the enterotoxin gene was higher in luminal washings of patients with diarrhea in the control group than in patients without diarrhea, but overall no difference was seen in the prevalences of the toxin gene in patients with and IBD than in the control group. One hypothesis to explain a potential pathogenic mechanism is that colonization with ETBF leads to acute or chronic intestinal inflammation (304); also, the enterotoxin may cleave E-cadherin, an intercellular adhesion protein forming the zonula adherens of intestinal epithelial cells (303) (which limits the ability of water or larger molecules to pass between cells), thus leading to the increased permeability of intestinal epithelial cells. In polarized cell monolayers, BFT alters the apical F-actin structure, resulting in disruption of the epithelial barrier function (39), which may consequently contribute to the diarrhea1 disease associated with *B. fragilis* infection (28).

Gut bacteria have been implicated as environmental factors in the inflammatory process of ulcerative colitis, a chronic inflammatory mucosal disease. The pANCA (perinuclear antineutrophil cytoplasmic antibody) autoantibody, which is di-

rected against neutrophil proteins, cross-reacted with a microbial antigen epitope in *E. coli* and *Bacteroides* (64). In *E. coli*, the epitope was located on the OmpC protein, one of the well-characterized porin proteins. In *B. thetaiotaomicron* and *B. caccae*, the epitope was found on ~80-kDa and ~100-kDa proteins, respectively.

Crohn's disease is a subacute or chronic inflammation of the GI tract that may include ulcers and granulomas (95). The role of the commensal bacteria in Crohn's disease and ulcerative colitis is currently being studied intensively (11, 269, 270). Some studies have implicated *E. coli* and *B. vulgatus* in the development of this disease. High titers of antisera to a 26-kDa antigen on the surface of *B. vulgatus* was found in patients with Crohn's disease (10), but the association of these bacteria with the disease process remains somewhat unclear (95). In a very recent report, two hypotheses of the nature of the bacterial role in IBD (including ulcerative colitis and Crohn's disease) are discussed (270). One theory attributes an excessive immunologic response to normal microflora to a malfunction in the immune system. The second theory suggests that changes in the composition of gut microflora and/or deranged epithelial barrier function elicits pathological responses from the normal mucosal immune system. The authors conclude that IBD is characterized by an abnormal mucosal immune response but that microbial factors and epithelial cell abnormalities are implicated in this response. Paneth cells, for example, produce defensins, which are small cationic peptides with antimicrobial activity. Lack of production of these peptides may allow higher bacterial concentrations in the ileal intestinal crypt, which could ultimately contribute to inflammation. Several studies indicated that the gut flora could drive mucosal inflammation, perhaps due to a lack of immune tolerance to the antigens in this flora.

Anaerobes in Pediatric Infections

Infections with intra-abdominal origin. Sites of *Bacteroides* infections in children mirror those found in adults. As in adults, *Bacteroides* isolates are most predominant in infections that have an intra-abdominal origin; normally present in the GI tract, these organisms may enter the peritoneal cavity due to a disturbance such as perforation, obstruction, or direct trauma. A few studies evaluating the microbiology of the peritoneal cavity and postoperative wounds in children following perforated appendix in pediatric patients found that *Bacteroides* species were recovered from 93% of peritoneal fluids, along with enteric gram-negative bacteria and enterococci (38). Complications following peritonitis may include subphrenic, hepatic, splenic, and retroperitoneal abscesses (39) (which may occur secondary to appendicitis), necrotizing enterocolitis, pelvic inflammatory disease, tubo-ovarian infection, surgery, or trauma (39). *B. fragilis* was the most common anaerobe found in postsurgical wound infections in wounds relating to the gut flora (37). As expected, wounds and other subcutaneous tissue infections in the rectal area, or that otherwise originated from the gut flora, are typically polymicrobial and often included *Bacteroides* species. A few studies found that ETBF was associated with diarrheal disease in young children 1 to 5 years of age (235).

Bone and joint infections in children. Anaerobes have rarely been reported as a cause of joint and bone infections in children. If found, anaerobic infections in arthritis typically involve a single isolate; the isolates found include anaerobic gram-negative bacilli (both *B. fragilis* group and *Fusobacterium* species), *Clostridium* spp., and *Peptostreptococcus* spp. Anaerobic arthritis is generally secondary to hematogenous spread. Anaerobic osteomyelitis will usually occur due to an anaerobic infection elsewhere in the body and may involve more than one organism (36). Some of these infections may result in positive blood cultures, and the organisms recovered are similar to those from the infected sites (46). Osteomyelitis involving long bones, which may occur after trauma or fracture, may also involve *Bacteroides* (35). A fairly recent review by Brook comments on the reports of the recovery of anaerobic organisms from infected bones in children (36).

Bacteremia in children. The incidence of anaerobic bacteremia in children appears to be lower than it is in adults (~1 to 8% of blood cultures) The particular anaerobe implicated in the bacteremia depends on the portal of entry and the underlying disease, and while other anaerobes are found, *Bacteroides fragilis* is the isolate most often recovered (36 to 64% of anaerobic blood culture isolates) (44). These infections are more likely to be found in children with predisposing conditions (e.g., malignancies, immunodeficiencies, renal insufficiency, or polymicrobial sepsis).

Infections in newborns. The involvement of anaerobes in infections in newborns is lower than that in older children. In newborns, anaerobes may be involved in cellulitis, aspiration pneumonia, infant botulism, conjunctivitis, and omphalitis (35). *Bacteroides* may be involved in cellulitis at the site of fetal monitoring (49). The fact that ETBF-associated diarrhea can be seen in children of 1 to 5 years but not in neonates suggests the possibility of maternal protection (192). In neonatal bacteremia, anaerobes are recovered in 2 to 12% of cultures, and close to half of those are *Bacteroides* species (47). The overall mortality noted was 26%, and mortality was highest with the *B. fragilis* group (34%). Inappropriate antimicrobial therapy was often a contributory factor for the high mortality (47). As mentioned above, ETBF is rarely found earlier than the age of 1 year; however, an ETBF strain was the sole organism isolated from the cerebrospinal fluid of a newborn with a complex congenital medullary-colonic fistula (4). No antibodies to the enterotoxin were found in the patient's serum.

Bacteroides as a Reservoir of Resistance Determinants

Clearly, human intestinal bacteria can have neutral or beneficial effects on human health and are, in fact, essential for the proper functioning of the digestive system. The other side of the coin is, in the words of Salyers et al., their "sinister role in human health as reservoirs for antibiotic resistance genes" (228). Thus, *Bacteroides* isolates, dwelling as seemingly innocuous members of the human colon, can serve as reservoirs of resistance determinants which they can pass on to much more virulent bacteria that move through the gut only periodically, even respiratory bacteria that are inhaled, swallowed, and pass

through the gut in 24 to 48 h. "Viewed in this way, the human colon is the bacterial equivalent of eBay," says Abigail Salyers, an expert on *Bacteroides* resistance and resistance transfer. "Instead of creating a new gene the hard way—through mutation and natural selection—you can just stop by and obtain a resistance gene that has been created by some other bacterium" (224).

This model suggests that human intestinal bacteria carry a variety of resistance genes that they can share among themselves (250). This genetic "elasticity" has permitted an unanticipated degree of transfer of resistance genes between species and suggests that multidrug resistance will continue to increase (108). The studies to support this model are retrospective in nature, comparing the DNA sequences of resistance genes found in different bacterial species of the human colon. Carriage of the tetracycline resistance gene (*tetQ*) in *Bacteroides* has increased from about 30% to more than 80%, and alleles of *tetQ* in different *Bacteroides* species were 96 to 100% identical at the DNA sequence level, which is what would be expected from horizontal gene transfer. Similarly, carriage of the *erm* gene rose from <2 to 23%. Furthermore, carriage of the *tetQ* and *erm* genes was also found in healthy people. If the genes found in different species are >95% identical, it is assumed that the gene was transferred horizontally from one species to the other (as opposed to two functionally similar proteins that evolved separately—in that case the DNA sequences can differ by more than 90%). Comparison of *erm* gene sequences found in other species that either do not normally reside in the human colon (*Streptococcus pneumoniae*) or reside there in low numbers (*Clostridium perfringens* and *Enterococcus faecalis*) with those in *Bacteroides* indicate that some transfer (direct or indirect) occurred between the species (250).

The elements containing resistance genes are remarkably stable, even in the absence of antibiotic pressure (227). One mechanism by which their stability is maintained may be the organization of genes into an integron, where the genes for antibiotic resistance are maintained in the same integron as enzymes that provide a benefit for the bacterium (e.g., the ability to colonize efficiently). Also, the ability to transfer these elements, coupled with the ability of tetracycline to induce transfer of these elements, makes it likely that bacteria exposed to low levels of tetracycline will have a tendency to transfer these elements to other bacteria that may have lost these genes (227).

Thus, aside from the danger posed by increasingly resistant *B. fragilis*, the possibility exists that even respiratory organisms such as *Klebsiella pneumoniae* (173) and *Acinetobacter baumanii* (60, 106, 125) may acquire resistance determinants from their temporary neighbors as they pass through the gut. Equally disturbing is the recent evidence that innocuous intestinal bacteria in cattle may be reservoirs for resistance and that mobile DNA elements (e.g., plasmids) were responsible for the rapid spread of drug resistance on farms whether or not therapeutic antibiotic use was involved (234). The likelihood of a meteoric rise in drug resistance is crystal clear; a strategy to halt or delay this potentially catastrophic development is, unfortunately, less obvious.

THE NITTY-GRITTY

Taxonomy

The genus *Bacteroides* has undergone major revisions in the past 15 years. The inclusion or exclusion of species within the genus *Bacteroides* changes frequently, and keeping up with the taxonomic revisions is a major undertaking. However, these changes are of importance both to clinicians and to clinical microbiologists, since taxonomic placement is a useful tool that can be an indicator of virulence potential or antimicrobial resistance. Familiarity with *Bacteroides* taxonomy can also influence the evaluation of published susceptibility assays and aid in predicting susceptibility of a clinical isolate. *B. thetaiotaomicron*, for example, is much more resistant to many antimicrobials than is *B. fragilis*, and omission of the more resistant species in a published antibiogram may give misleading results.

In 1989 to 1990, the species within *Bacteroides* were restricted to members of the *B. fragilis* group (241), and most of the clinically relevant species that were not retained in the genus *Bacteroides* were placed in the genus *Porphyromonas* (242) or *Prevotella* (240). *Bacteroides gracilis*, which is often involved in deep-seated infections (126), was moved to the genus *Campylobacter* and renamed *Campylobacter gracilis* (286). More recently, a host of other genera were described for *Bacteroides* species, including, among others, *Dialister*, *Megamonas*, *Mitsuokella*, *Tannerella*, *Tissierella*, and *Alistipes* (260).

Often by using culture-independent approaches such as 16S rRNA gene sequencing, a variety of new species have added to the total number of *Bacteroides* species (now >20). In the fall of 2005, several species were added to the genus *Bacteroides*, including *Bacteroides goldsteinii* (261), *Bacteroides nordii* and *Bacteroides salyersai* (262), *Bacteroides plebeius* and *Bacteroides coprocola* from human feces (135), and *Bacteroides massiliensis* isolated from the blood culture of a newborn (86). Recently, *B. goldsteinii*, along with *Bacteroides distasonis* and *Bacteroides merdae*, were moved to a new genus, *Parabacteroides* (225).

Isolation and Identification

Laboratories experienced in processing specimens for anaerobic bacteria will be familiar with the principles used in isolating and identifying *Bacteroides* strains, and the reader is referred to the *Wadsworth-KTL Anaerobic Bacteriology Manual* (127) and the *Manual of Clinical Microbiology* (128). A very brief summary of points to be aware of in processing the specimen is as follows: (i) collect the specimen in a manner to avoid contamination with normal flora; (ii) use an oxygen-free transport medium system and avoid drying; (iii) *Bacteroides* spp. grow relatively rapidly compared to most other anaerobes, and their growth on selective medium (e.g., *Bacteroides* bile esculin agar) is quite distinctive; and (iv) *B. fragilis* is resistant to kanamycin, vancomycin, and colistin and is stimulated by 20% bile (which is inhibitory for most other anaerobic organisms [except *Bilophila*]). Other tests to identify the species of *Bacteroides* isolates are listed in the *Wadsworth-KTL Anaerobic Bacteriology Manual* (127).

Several PCR schemes to identify *Bacteroides* species to the genus and/or species level have been developed. One report developed group-specific primers to the β-isopropylmalate de-

hydrogenase gene *leuB* and found that this was a useful tool for rapid diagnosis of *Bacteroides* infections (159). Our laboratory developed a multiplex PCR system with group- and species-specific primers to rapidly identify species of the *B. fragilis* group (146). Using the latter technique, 10 species of the *B. fragilis* group could be identified.

Physiology

Bacteroides species are a pleomorphic group of non-spore-forming gram-negative anaerobic bacteria. The cell envelope of *B. fragilis* is a particularly complex structure consisting of multiple layers, with subunits of one layer protruding through another. Descriptions of these layers come both from structural and functional studies, but results of these studies have not necessarily provided consistent descriptions either of the makeup, function, or relationship to each other of these layers. We have recently published a detailed review of the cell surface structures of *Bacteroides* (199), and they will be described briefly here. The *B. fragilis* capsule has already been discussed at length in a previous section ("The bacterial capsule").

Cell Surface Structures

Pili, fimbriae, and adhesins. The terms pili, fimbriae, and adhesins are not very distinctly defined. Although adhesins (for example, pili and fimbriae used in adhesion) are often protein, the term is not restricted to protein adhesins, and other structures may be implicated. *B. fragilis* may possess peritrichous fimbriae (178). These fimbriae have been implicated in adhesion; in one study, trypsin treatment of clinical isolates of *B. fragilis* inhibited both hemagglutination and adhesion to a human intestinal cell line, suggesting that the responsible adhesins were proteins (87). In various studies, pili have also been implicated in hemagglutination and adhesion (51, 193). Other studies, however, implicated the polysaccharide capsule rather than the protein appendages (177). Recent functional genomic studies classifying databases of specific molecules note that members of the *Bacteroides* secrete large numbers of lipoproteins with an N-terminal beta-propeller domain, which may form a specialized adhesion module (7, 20). Discrepancies among the various studies may be due to differences in the cell lines used, differences in the pilus type studied, or differences in the capsule characteristics of the particular strains.

Lectin-like adhesins have been demonstrated in *B. fragilis* (218); correspondingly, sialic acid and other sugars, as well as macromolecules rich in sialic acid, have been identified as the receptors for these adhesins (77). In some cases, the adhesin will bind to the receptor residue only after neuraminidase treatment (110). Indeed, many *B. fragilis* strains have neuraminidase activity, and Guzman et al. (110) suggest that the bacterial removal of the terminal sialic acid may serve as a mechanism to expose the adhesion sites in a two-step adhesion process. Others found that adherence to WiDr cells and hemagglutination were not affected by neuraminidase activity (167). Hemagglutination appears to be caused by more than one adhesin, at least one of which is a carbohydrate (probably the capsule), with the pili assuming this role in noncapsulated strains (15). Recently, a surface glycoprotein of *B. fragilis* was implicated in binding to one of the laminin proteins that make part of the extracellular matrix that underlies epithelial, endothelial, and surrounding connective tissue cells (74).

Fibrils. Fibrils are a class of bacterial appendage consisting of polysaccharide and associated proteins and are much finer and often much shorter than pili. In fact, they may be impossible to distinguish from long LPS side chains in transmission electron microscopy, since the lengths quoted for these structures overlap. However, peritrichous fibrils were reported in only one out of 19 *B. fragilis* strains studied (178), and these were distinguished from the capsule, pili, and ruthenium red staining layer (probably composed mostly of LPS side chains). Again, not all cells of a given population exhibited these fibrils. Little is known about the function of these fibrils, and their role in adhesion and biofilm formation remains to be determined.

LPS. The LPS side chains project from the lipid moiety that is anchored in the outer membrane, forming a visible fringe in transmission electron microscopy (the exact nature of this layer remains to be determined, but most authors assume that the fringe overlying the outer membrane comprises the LPS side chains.) In our own recent studies, we noted significant variation in the height and density of the LPS fringe between individual colonies within the same cell population grown under the same conditions (199).

Outer membrane proteins. Several membrane proteins have so far been characterized in *B. fragilis*. We demonstrated that OmpA was the major outer membrane protein in *B. fragilis* (302), and our studies further suggest that *B. fragilis* OmpA1 is important in maintaining cell structure (unpublished data). We identified four distinct genes that encode OmpA homologs and found that all four *ompA* genes are transcribed in *B. fragilis*. In other bacteria OmpA has been shown to be associated with virulence (292), but we have not yet studied this in *B. fragilis*.

Two porin proteins, *B. distasonis* HMP-1 and *B. fragilis* Omp200 (a two-component porin protein composed of Omp121 and Omp71), were described by our laboratory (297, 301). The Omp121 component of Omp200 of *B. fragilis* had some homology to *B. thetaiotaomicron* SusC; genomic analysis has indicated that one group of SusC homologs in this species are positioned upstream of SusD homologs that may be involved in acquisition or utilization of polysaccharides (308). The other group of the SusC homologs (including Omp121) are positioned upstream of homologs of Omp71, a protein whose function is not yet defined. Xu and Gordon speculated that many of the organism's SusC homologs are conserved components of a series of multifunctional outer membrane porins (308). Researchers in other laboratories have described a 45-kDa porin-like protein and 51-, 92-, and 125-kDa porin-like proteins (130, 171). Two large porins of 210 and 135 kDa that include the 45-kDa outer membrane protein were also described (170).

The membrane also contains an iron-regulated outer membrane protein involved in heme uptake (176). Iron starvation triggers the expression of this heme importer. Since iron is limiting in the host, iron uptake mechanisms are undoubtedly an important colonization factor. There is apparently no evidence for the secretion of iron chelators by *B. fragilis*.

Outer membrane vesicles. *Bacteroides fragilis* characteristically produces numerous outer membrane vesicles. These vesicles appear in transmission electron microscopy as surface

blebs and detached extracellular vesicles and have been shown to have a hemagglutinin function (185) and to contain sialidase activity that may be correlated to virulence (78). Similar outer membrane vesicles have been observed in *Porphyromonas gingivalis*, *Pseudomonas fragi*, and *Xenorhabdus nematophilus*, where it has been suggested that they may serve as a vehicle for toxins and attachment to host cells (80, 109, 132). Furthermore, similar vesicles in *Pseudomonas aeruginosa* have been shown to carry quinolone signaling molecules for intercellular signaling (153). Vesicle production varies considerably between strains of *B. fragilis*; we noted that these vesicles are produced in large amounts by certain clinical isolates but are almost entirely absent in others (199).

Export systems. The genomic studies of *B. fragilis* did not show evidence of type III, IV, autotransporter, or two-partner secretion systems. There were genes for Hly type I secretion systems, which are similar to the hemolysin type I secretion system HlyDb from *E. coli* (288), or the type II general secretion pathway (54). The large quantity of enzyme-containing outer membrane vesicles produced by *B. fragilis* (185) suggests that this may be an important export pathway (54). The *Bacteroides* genome also contains large numbers of gene homologs of a variety of efflux pumps systems whose export functions have not yet been defined. *Bacteroides fragilis* may secrete two toxins into the medium: endotoxin (LPS) and BFT (fragolysin). Intracellular, periplasmic and outer membrane-bound proteases have been identified in *B. fragilis* (101). Many of the hydrolytic enzymes, which are generally considered to be pathogenic factors, may be membrane bound and/or secreted into the medium. Many histolytic enzymes are associated with the *Bacteroides* cells during exponential phase but are released in stationary phase, apparently without cell lysis (149). Determining the exact location of hydrolytic enzymes at different phases of growth would aid the understanding of their possible role as invasins.

Bacteriocins. Bacteriocins are antibacterial chemicals secreted by bacteria to inhibit competitors. Analysis of clinical isolates of *B. fragilis* revealed that intestinal isolates secreted high levels of a bacteriocin protein, and they themselves were highly resistant to bacteriocins secreted by other *B. fragilis* strains, while nonintestinal isolates produced only medium levels of bacteriocins and were less resistant (5). A bacteriocin protein has been shown to be produced by a *B. fragilis* strain that inhibited the RNA polymerases only of other *B. fragilis* strains in vivo (165). This narrow specificity is typical of bacteriocins that bind to specific receptors and attack species or strains closely related to the producer. Presumably, this is a mechanism to reduce competition between strains occupying the same ecological niche.

Resistance to bile. In the host, bile functions as a biological detergent with an essential role in fat digestion (i.e., it emulsifies and solubilizes lipids). Deconjugated bile salts are less efficiently reabsorbed than conjugated bile salts; this results in greater excretion of free bile acids in feces, which may result in greater use of cholesterol for de novo synthesis of bile to compensate for this loss. This increased utilization of cholesterol may lower serum cholesterol levels. Alternatively, the lowered ability of free bile salts to solubilize cholesterol may reduce the absorption of cholesterol through the intestinal lumen and into the serum (17). *B. fragilis* plays a key role in the

enterohepatic circulation of bile acids by helping the process of biotransformation between conjugated and deconjugated bile salts. *B. fragilis* contains many enzymes required for these reactions, including a bile salt hydrolase (66, 267). In turn, these organisms must be able to survive when exposed to the high concentration of bile salts in the intestinal tract. The detergent activity of bile salts permeabilizes bacterial membranes and can eventually lead to membrane collapse and cell damage (16, 34, 70). Factors that enable *Bacteroides* species to tolerate bile salts are important elements in their ability to survive in the gut. On the other hand, exposure to bile may initiate other survival mechanisms. For example, we have demonstrated that expression of the RND efflux pumps of *B. fragilis* is increased in response to stress by bile and bile salts (197). Bile salt hydrolase activity may have both beneficial (e.g., in lowering cholesterol levels) and deleterious (e.g., unconjugated bile acids are less efficient than conjugated molecules in digestion of lipids) effects for the host (17).

Oxidative stress response. The ability of *B. fragilis* to grow in the presence of nanomolar concentrations of O_2 has important implications for the interaction of this opportunistic pathogen with its oxygenated hosts. During the establishment of an infection, the ability to grow in the presence of nanomolar concentrations of O_2 would enable proliferation in host tissues even before the anaerobic abscess is formed (13). Many studies of the oxidative stress response in *B. fragilis* have focused on the ability of enzymes to detoxify or otherwise protect the organism from oxygen radicals; these proteins include catalase, superoxide dismutase, alkyl hydroperoxide reductase, and nonspecific DNA binding protein (32, 217, 271). These genes are, in part, under the control of the redox-sensitive regulator OxyR (253). Recently, six new genes were identified upon exposure of *B. fragilis* to O_2, including an aspartate decarboxylase gene, a putative outer membrane protein gene, a cation efflux pump gene, a heat shock protein gene, and two ribonucleotide reductase genes which may have a role in maintaining deoxyribonucleotide pools for DNA repair and growth recovery (253).

Susceptibility Patterns of *Bacteroides*

Bacteroides species are most commonly found in mixed infections, and the commonly prescribed treatments are designed accordingly. Frequently prescribed antibiotics include β-lactams (with or without β-lactamase inhibitors), carbapenems, clindamycin, and metronidazole. Fluoroquinolones are also used in combination with clindamycin and metronidazole (41). *Bacteroides* species are potentially resistant to a broad range of antibiotics, and resistance to a given antimicrobial can vary greatly between geographical locations and institutions.

Resistance rates can also vary widely among the different species of the *Bacteroides fragilis* group. For example, reported resistance rates vary widely for clindamycin (15 to 44%), cefotetan (13 to 94%), and cefoxitin (3.5 to 41.5%) (63). Resistance to even the most active drugs, such as imipenem, piperacillin-tazobactam, ampicillin-sulbactam, and metronidazole, is found in occasional strains (201, 236, 290). Frequently, the other species in the *B. fragilis* group are more resistant than *B. fragilis* to many antibiotics. Current antibiograms of anaerobic bacteria have been summa-

rized and reviewed recently (114, 115, 256, 258) and results of several studies have been collated in Table 3.

The most recent multicenter study by Snydman and colleagues reviewed results for 11 antimicrobials and more than 5,000 isolates referred by 10 medical centers (256) and presented the results as trends of antimicrobial susceptibility over an 8-year time period. Resistance to carbapenems was rarely seen in this study (<1.5%). The trends in resistance to piperacillin-tazobactam, ampicillin-sulbactam, and cefoxitin were species dependent and did not necessarily correlate with each other. A worrisome development was the increase in resistance of *B. distasonis* (which is no longer technically in the genus *Bacteroides* [225]) to ampicillin-sulbactam in 2002 and 2004 (>20%). Resistance of *B. fragilis*, *B. ovatus*, and *B. thetaiotaomicron* to clindamycin increased significantly, as did the geometric mean MICs of these agents; similar results were seen for moxifloxacin. Resistance rates for tigecycline were low and stable during the 5-year period during which this agent was studied.

Mechanisms of Antimicrobial Resistance

Species of the genus *Bacteroides* have the most antibiotic resistance mechanisms and the highest resistance rates of all anaerobic pathogens (259). *B. fragilis* is intrinsically resistant to several classes of structurally unrelated antibiotics (114), and the mechanisms are often poorly understood. Logically, resistance to any antimicrobial agent should be due to one of three mechanisms: altered target binding affinity, decreased penetration for the antibiotic due to permeability or efflux changes, or the presence of an inactivating enzyme. Clinically, *Bacteroides* species have exhibited increasing resistance to many antibiotics, including cefoxitin, clindamycin, metronidazole, carbapenems, and fluoroquinolones (e.g., gatifloxacin, levofloxacin, and moxifloxacin). The newer fluoroquinolones, including sitafloxacin, clinafloxacin, and garenoxacin, are generally more active against *Bacteroides* species (257). *Bacteroides* species are adept at antimicrobial evasion and may use any or all of the above-mentioned mechanisms to thwart effective clinical therapy.

β-Lactam agents. The most common mechanism of resistance to β-lactam agents is β-lactamase (product of the *cepA* gene), a chromosomally encoded class 2e cephalosporinase (113), which is found in nearly all *Bacteroides* species (219). This enzyme is inhibited by the most commonly used β-lactamase inhibitors (sulbactam, clavulanic acid, and tazobactam), and agents containing these inhibitors are active against strains that produce the β-lactamase enzyme. The cefoxitin resistance gene, *cfxA* (182), has been shown to be distantly related to the *B. fragilis* endogenous *cepA* (219).

Carbapenems. Resistance to carbapenems remains rare. Genes for two enzymes that can degrade these agents have been identified: *cfiA* and *ccrA*, both encoding class B metallo-β-lactamases (147). These enzymes confer resistance to carbapenems, β-lactams, and β-lactamase inhibitor combination agents. Some strains of *Bacteroides* contain "silent" carbapenemase genes, and expression levels are dependent on promoter-containing insertion sequences (IS) inserted upstream of the *cfiA/ccrA* gene sequence. Changes in penicillin binding proteins (PBPs) or changes in porins that allow permeation of the carbapenems are other theoretically possible carbapenem resistance mechanisms but have only rarely been described in clinical isolates (e.g., PBP2Bfr, a homolog of *E. coli* PBP3, was implicated in imipenem resistance in one strain [6]). On the other hand, we have recently studied multidrug-resistant strains with increased efflux pump activity, and we have found clinical isolates that are resistant to carbapenems because of increased efflux activity (194, 201).

PBPs. Penicillin and other β-lactams are cell wall-active drugs that interfere with the final transpeptidation step in the synthesis of the peptidoglycan. The structure of the β-lactam antibiotics facilitates their binding to the active site of PBPs; this irreversible inhibition of the PBPs prevents the final cross-linking (transpeptidation) of the nascent peptidoglycan layer. The correlation of β-lactam activity and PBP affinity in *B. fragilis* has not been straightforward, partly because there are conflicting results from investigations into the numbering and molecular masses of PBPs from this bacterium. Most studies were done by labeling cells or cell extracts with a labeled antimicrobial and analyzing the results by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (82, 83, 298). The completion of the genome sequence of *B. fragilis* allowed a more complete analysis, and seven putative PBP genes were identified. The gene sequences for the closest homologs to the *E. coli* PBPs in the *B. fragilis* genome (pbp1abBfr, pbp1cBfr, pbpABfr, pbpBBfr, pbp4Bfr, and pbp7Bfr) were deduced as the orthologs for the *E. coli* genes ponBEco (PBP1bEco), pbpCEco (PBP1cEco), pbpAEco (PBP2Eco), pbpBEco (PBP3Eco), dacBEco (PBP4Eco), and pbpGEco (PBP7Eco), respectively (188). In any case, as the authors finally conclude, it is very difficult to correlate the 50% inhibitory concentration affinity of a particular PBP for an antibiotic with the MIC, since this is not generally the only mechanism responsible for the resistance.

In spite of this difficulty, several workers have reported an association between the reduced affinity of β-lactam compounds for the PBPs of *Bacteroides* species and resistance to these agents. Reduced affinity of an 80-kDa PBP for imipenem, piperacillin, cefoperazone, cefotaxime, and ceftazidime was observed in a resistant strain of *B. fragilis*, although no precise 50% inhibitory concentration calculations were performed (99). Alterations in PBPs, mainly changes in PBP1 and/or PBP2, have been implicated in non-β-lactamase-mediated cefoxitin resistance in cefoxitin-resistant mutants of *B. fragilis* group species (187, 298). The affinities of the PBP1 complex (86 kDa) of *B. thetaiotaomicron* 238m for cefoxitin and piperacillin were >100-fold and ~70-fold reduced, respectively, compared with those of its parent strain (85). The ortholog of the *E. coli* PBP3 gene (pbpBBfr, which encodes the protein PBP2Bfr) was implicated in binding to imipenem (6, 188).

Outer membrane proteins. There are some data correlating changes in outer membrane porin proteins and antimicrobial resistance in *Bacteroides*. A 45-kDa porin-like protein from *B. fragilis* was potentially correlated with antibiotic resistance in *B. fragilis* (171), and a putative porin of ~70 kDa of *B. thetaiotaomicron* was potentially associated with resistance to β-lactam agents (18). To date, however, the relationships between outer membrane (porin) proteins and antimicrobial resistance have been associative, and no definitive correlation has been shown.

TABLE 3. Susceptibility of *Bacteroides* species to antimicrobial agents

Organism	Antimicrobial	MIC (μg/ml)			% of isolates			Reference
		90%	Geometric mean	Breakpoint	Susceptible	Intermediate	Resistant	
B. fragilis	Amoxicillin + clavulanic acid	>64		≥16/8			4.8	19
	Ampicillin-sulbactam	16					1.7	256
	Cefotetan	64		≥64			19	19
	Cefoxitin	32		≥64			3.4	255
	Cefoxitin	32					5.2	256
	Ceftriaxone	>32	25.7		15	48	37	296
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	2						257
	Clindamycin	>128		≥8			24.9	255
	Clindamycin	256					19.3	256
	Doripenem	1	0.5		96	3	1	296
	DX-619	0.5						275
	Ertapenem	0.5	0.3		100	0	0	296
	Garenoxacin	4		≥4			14.8	255
	Garenoxacin	0.5						81
	Imipenem	0.5	0.2		100	0	0	296
	Levofloxacin	2	1.5		91	5	4	296
	Linezolid	8		≥4			94.3	255
	Meropenem	0.5	0.2		97	3	0	296
	Metronidazole	4		≥32			0.5	19
	Metronidazole	2			100	0	0	24
	Moxifloxacin	8		≥4			36.4	255
	Moxifloxacin	8					27.3	256
	Moxifloxacin	1						81
	Moxifloxacin	4						25
	Moxifloxacin	8						257
	NVP-LMB415	0.5		≥4			0	255
	Piperacillin-tazobactam	4					0.4	256
	Sitafloxacin	1						257
	Ticarcillin	>256		≥128			28.6	19
	Ticarcillin + clavulanic acid	4		≥128/2			1.6	19
	Tigecycline	8		≥4			14.8	255
	Tigecycline	8					5.1	256
	Tigecycline	8						24
B. ovatus	Cefoxitin	32		≥64			6.2	255
	Ceftriaxone	>32	25		20	50	30	296
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	4						257
	Clindamycin	>128		≥8			40.6	255
	Doripenem	1	0.4		100	0	0	296
	DX-619		1.125					275
	Ertapenem	1	0.5		100	0	0	296
	Garenoxacin	8		≥4			31.3	255
	Garenoxacin	1						81
	Imipenem	0.5	0.2		100	0	0	296
	Levofloxacin	16	7.5		0	25	75	296
	Linezolid	8		≥4			78.1	255
	Meropenem	0.5	0.2		100	0	0	296
	Metronidazole	4			100	0	0	24
	Moxifloxacin	64		≥4			81.3	255
	Moxifloxacin	2						81
	Moxifloxacin	32						257
	Moxifloxacin	16						25
	NVP-LMB415	0.25		≥4			0	255
	Sitafloxacin	4						257
	Tigecycline	8		≥4			18.8	255
	Tigecycline	16						24
B. thetaiotaomicron	Cefoxitin	64		≥64			10.5	255
	Ceftriaxone	>32	31.1		2	58	40	296
	Ceftriaxone	>32	30.3		4	53	43	296
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	4						257
	Clindamycin	>128		≥8			42.1	255
	Doripenem	2	0.6		98	0	2	296
	Doripenem	1	0.6		100	0	0	296
	DX-619	0.5						275
	Ertapenem	2	0.6		100	0	0	296
	Ertapenem	2	0.6		100	0	0	296
	Garenoxacin	4		≥4			18.4	255
	Garenoxacin	2						81
	Imipenem	1	0.4		100	0	0	296
	Levofloxacin	8	6.3		2	2	69	296
	Levofloxacin	16	3.9		52	13	35	296
	Linezolid	8		≥4			93.4	255
	Meropenem	0.5	0.3		100	0	0	296
	Meropenem	0.5	0.3		100	0	0	296
	Metronidazole	2			100	0	0	24

TABLE 3—*Continued*

Organism	Antimicrobial	MIC (µg/ml)			% of isolates			Reference
		90%	Geometric mean	Breakpoint	Susceptible	Intermediate	Resistant	
	Moxifloxacin	32		≥4			47.4	255
	Moxifloxacin	2						81
	Moxifloxacin	8						25
	Moxifloxacin	32						257
	NVP-LMB415	0.025		≥4			0	255
	Sitafloxacin	4						257
	Tigecycline	8		≥4			27.6	255
	Tigecycline	8						24
B. distasonis	Cefoxitin	128		≥64			39.3	255
	Clinafloxacin	8						257
	Clindamycin	>128		≥8			21.4	255
	DX-619	1						275
	Ertapenem	4	1.77				1.5	256
	Garenoxacin	8		≥4			35.7	255
	Garenoxacin	1						81
	Imipenem	2		≥16			0	255
	Imipenem	2	0.95				0.4	256
	Linezolid	4		≥4			92.9	255
	Meropenem	2	0.58				1.1	256
	Moxifloxacin	32		≥4			50.0	255
	Moxifloxacin	2						81
	Moxifloxacin	16						25
	Moxifloxacin	32						257
	NVP-LMB415	0.5		≥4			0	255
	Sitafloxacin	4						257
	Tigecycline	8		≥4			39.3	255
B. uniformis	Cefoxitin	32		≥64			4.5	255
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	4						257
	Clindamycin	>128		≥8			18.2	255
	Ertapenem	2	0.88				0.5	256
	Garenoxacin	8		≥4			27.3	255
	Garenoxacin	>8.0						81
	Imipenem	0.5		≥16			0	255
	Imipenem	1	0.43				0.5	256
	Linezolid	8		≥4			68.2	255
	Meropenem	1	0.41				0.5	256
	Metronidazole	4			100	0	0	24
	Moxifloxacin	64		≥4			59.1	255
	Moxifloxacin	32						25
	Moxifloxacin	>8.0						81
	Moxifloxacin	32						257
	NVP-LMB415	0.25		≥4			0	255
	Sitafloxacin	4						257
	Tigecycline	8		≥4			18.2	255
	Tigecycline	8						24
B. vulgatus	Cefoxitin	32		≥64			4.5	255
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	16						257
	Clindamycin	>128		≥8			50.0	255
	Ertapenem	2	0.82				0.3	256
	Garenoxacin	16		≥4			50.0	255
	Garenoxacin	1						81
	Imipenem	1		≥16			0	255
	Linezolid	4		≥4			68.2	255
	Meropenem	1	0.47				0.0	256
	Metronidazole	4			100	0	0	24
	Moxifloxacin	64		≥4			72.7	255
	Moxifloxacin	4						81
	Moxifloxacin	4						25
	Moxifloxacin	128						257
	NVP-LMB415	0.5		≥4			0	255
	Sitafloxacin	16						257
	Tigecycline	4		≥4			18.2	255
	Tigecycline	8						24
B. fragilis group	Amoxicillin + clavulanic acid	4		≥16/8			5.6	19
	Cefotetan	>128		≥64			44	19
	Cefoxitin	32		≥64			7.4	255
	Chloramphenicol		8		100	0	0	24
	Clinafloxacin	4						257
	Clindamycin	>128		≥8			30.9	255
	Ertapenem	4	1.04				1.0	256
	Garenoxacin	8		≥4			21.2	255
	Imipenem	1		≥16			0.07	255

TABLE 3—*Continued*

Organism	Antimicrobial	MIC (µg/ml)			% of isolates			Reference
		90%	Geometric mean	Breakpoint	Susceptible	Intermediate	Resistant	
	Imipenem	1	0.38				0.4	256
	Linezolid	8		≥4			90.2	255
	Meropenem	1	0.42				0.6	256
	Metronidazole	2		≥32			0.3	19
	Metronidazole	2			100	0	0	24
	Moxifloxacin	32		≥4			48.0	255
	Moxifloxacin	4						25
	Moxifloxacin	32						257
	NVP-LMB415	0.5		≥4			0	255
	Sitafloxacin	2						257
	Ticarcillin	>256		≥128			33.7	19
	Ticarcillin + clavulanic acid	16		≥128/2			2.2	19
	Tigecycline	2		≥4			20.1	255
	Tigecycline	8						24
Other *Bacteroides* spp.	Cefoxitin	32		≥64			0	255
	Chloramphenicol	8			100	0	0	24
	Clinafloxacin	4						257
	Clindamycin	>128		≥8			31.3	255
	Ertapenem	4	1.03				0.5	256
	Garenoxacin	4		≥4			25.0	255
	Imipenem	0.05		≥16			0	255
	Linezolid	8		≥4			100	255
	Meropenem	1	0.4				0.5	256
	Metronidazole	4			100	0	0	24
	Moxifloxacin	32		≥4			81.3	255
	Moxifloxacin	16						257
	NVP-LMB415	0.5		≥4			0	255
	Sitafloxacin	2						257
	Tigecycline	8		≥4			25.0	255
	Tigecycline	8						24

Aminoglycosides. *Bacteroides* species are inherently resistant to aminoglycosides (protein synthesis inhibitors that bind the 30S subunit of the ribosome), as uptake of this drug requires an oxygen- or nitrate-dependent electron transport chain which is lacking in these anaerobes (52).

Macrolides, lincosamides, and chloramphenicol. Macrolides (e.g., erythromycin) inhibit protein synthesis by binding to the 23S rRNA molecule (in the 50S subunit) of the bacterial ribosome, blocking the exit of the growing peptide chain. Lincosamides (e.g., clindamycin) also bind to the 50S ribosomal subunit. Resistance to clindamycin, a commonly used antianaerobic drug during the last few decades, has increased steadily. Homologs of the macrolide-lincosamide-streptogramin B resistance genes confer both clindamycin and erythromycin resistance in *Bacteroides* (89, 215). These genes are similar to the macrolide-lincosamide-streptogramin B resistance genes in gram-positive organisms that cause resistance by methylation of the ribosome target.

Chloramphenicol binds to the ribosomal peptidyl transferase in bacteria and thus prevents protein biosynthesis; the enzyme chloramphenicol acetyltransferase transfers an acetyl group from acetyl coenzyme A to the primary hydroxyl on C-6 of chloramphenicol, preventing the modified antibiotic from binding to the ribosome and exerting its effect (33). In the most recent national survey of multiple hospitals within the United States, no resistance to chloramphenicol (MIC, >16 µg/ml) was seen (256). However, the MICs of chloramphenicol seem to cluster just around breakpoint levels (in our own studies, we have seen many strains of *B. fragilis* with chloramphenicol MICs of 8 µg/ml [300]), so a slight shift of MICs could change this picture, since many strains would then be considered resistant.

Tetracycline. Tetracyclines inhibit bacterial protein synthesis by blocking the attachment of the tRNA-amino acid to the ribosome. This agent was once the first-line antibiotic for treatment of anaerobic infections, and all strains of *Bacteroides* isolated in the 1950s were susceptible (103). This antibiotic remained a useful antianaerobic agent until the early 1970s (134); today, nearly all clinical isolates of *Bacteroides* are resistant (80 to 90%). *tetQ* is one of several tetracycline resistance genes that codes for a cytoplasmic protein that interacts with the ribosome, making it insensitive to tetracycline blocking (232). TetQ is the most common type of tetracycline resistance in *Bacteroides* (140). Efflux of tetracycline has also long been described as a resistance mechanism in *B. fragilis* (203).

Nitroimidazoles. Metronidazole is a commonly used drug for anaerobic infections and resistance to this drug is rare, but there is evidence both of increasing resistance and of artificially low resistance rates, in some cases, due to the screening method used for detecting anaerobes. The true incidence of metronidazole resistance of *B. fragilis* may be much higher than normally assumed, at least in the United Kingdom, where most laboratories use resistance to metronidazole as an indication that the organisms are facultative anaerobes (as opposed to obligate anaerobes with reduced susceptibilities to metronidazole) (30, 290); thus, a metronidazole-resistant *B. fragilis* strain would be mistakenly assumed to be a facultative aerobe and not tested further.

Resistance is generally attributed to changes in the *nim* genes or associated genes (e.g., IS) (30, 56, 75, 259). The *nim* gene can be "silent" unless activated by IS elements (111). Four *nim* genes (*nimA* to -*D*) can occur in all *Bacteroides* species; each of these genes is associated with a distinct mobile genetic element, and each also has a specific activating IS

element (111, 148, 211, 278). The presence of any one of these genes can be detected by PCR (279). Three additional *nim* genes (*nimE*, *nimF*, and *nimG*) have also been described (148), but less is known about their mobility and association with IS elements. However, the presence of a *nim* gene does not necessarily confer clinical levels of metronidazole resistance; in some cases, the gene may not be expressed or may be expressed only at very low levels (96).

Quinolones. Quinolones inhibit two specific enzymes, DNA gyrase and DNA topoisomerase IV, which aid in bacterial DNA replication, and mutations in these enzymes are the most common causes of quinolone resistance. Mutations in GyrA causing fluoroquinolone resistance in *B. fragilis* have been identified at hot-spot positions 82 and 86 (equivalent to positions 83 and 87 in *E. coli*) (174, 213). Substitutions in GyrB, ParC, and ParE have so far proven uncommon and are not well established in *B. fragilis*. Bacteria may also become resistant by increased export of quinolones out of the cell, and Miyamae et al. found active efflux of norfloxacin by *B. fragilis* and suggested that the efflux is catalyzed by a pump similar to that of NorA/Bmr (160). Also, *B. thetaiotaomicron* possesses a MATE (multidrug and toxic compound extrusion) family multidrug efflux exporter (BexA) that pumps out fluoroquinolones (161). We have also demonstrated quinolone resistance in clinical isolates and in laboratory mutants that is due to increased efflux activity of pumps of the RND family (194, 196, 200, 201).

IS Elements

IS typically contain DNA coding for a transposase that allow this element to generate mutations and genome rearrangements, as well as sometimes providing efficient promoters, either carried entirely by the IS element or created as a result of the hybrid sequence between the IS and the target sequence. This is the case for the IS-borne promoters that can be found upstream of the *cfiA* or *ccrA* gene (189), macrolide resistance genes (205), and metronidazole resistance *nim* genes (259, 278).

Mobile Genetic Elements in *Bacteroides*

Bacteroides species, like other bacteria, have a variety of mechanisms for exchanging genetic information. The frequent presence of mobile genetic elements in *Bacteroides* is not merely an interesting topic for molecular biologists but critically relevant to both the clinical microbiologist and the infectious disease practitioner. These elements are vitally important in the spread of antibiotic resistance genes. Mobile elements found in *Bacteroides* include plasmids, transposons, conjugative transposons, and bacteriophages (254), and all but bacteriophages have been implicated in transfer of antimicrobial resistance genes.

Plasmids. Plasmids are very common in *Bacteroides* species and are found in ~20 to 50% of strains (254). Plasmids typically replicate as separate elements in the host cell, although there are some plasmids in other genera that can either integrate into the chromosome or replicate as plasmids, depending on the host (231). Many plasmids possess *oriT* and a *trans*-acting mobilization gene, which allow them to be transferred by conjugation (note that *trans*-acting factors may act on enti-

ties that are not in close proximity.) There are also plasmids that do not self-transfer but may be transferred via mobilization by other chromosomal elements (e.g., pBFTM10) (254).

Genes conferring resistance to many different classes of antibiotics have been found on plasmids in *Bacteroides*. Resistance genes *nimA* to *-F*, which have been implicated in sporadic cases of metronidazole resistance in several hospitals worldwide, have been identified on transferable plasmids (56, 148, 279). Transferable plasmid-linked chloramphenicol acetyltransferase conferring high-level resistance was observed in a clinical isolate of *Bacteroides uniformis* (152). The *cfiA* gene, conferring resistance to carbapenems, has also been found on a 6.4-kb plasmid in clinical isolates (166). Clindamycin and erythromycin resistance can be transferable between *Bacteroides* species, either via a chromosomal element (273) or in association with a conjugative plasmid (249, 294).

Conjugative transposons. Transposons, both mobilizable and conjugative, do not replicate independently; rather, they excise from and integrate into chromosomal DNA and are copied along with the chromosomal DNA. Conjugative transposons have a mechanism of excision and integration that resemble some features of both plasmids and bacteriophage (231). Conjugative transposons are practically ubiquitous among the *Bacteroides*: over 80% of *Bacteroides* strains contain at least one conjugative transposon (250).

The particular attributes of conjugative transposons have been elegantly summarized by Salyers et al. (231). Conjugative transposons have certain characteristics of plasmids, of transposons, and of phages. Often, but not always, they are designated by CTn (conjugative transposon) as opposed to Tn (transposon). The conjugative transposons of *Bacteroides* belong to at least two families; CTnDot is the best described (231, 254). Often, the name of the strain in which they are found is added to the designation (e.g., CTnDot, found in the DOT strain of *B. thetaiotaomicron*). In addition to being able to insert into the chromosome, *Bacteroides* conjugative transposons can insert into coresident plasmids and mobilize them in *cis* (i.e., they can act on entities that are physically adjacent) by integrating themselves into the plasmid and facilitating transfer of the plasmid-conjugative transposon hybrid into another cell (230). They can also mobilize coresident plasmids "in *trans*" by supplying factors needed to facilitate transfer of the plasmid, while remaining physically separate from the plasmid.

The conjugative transposons do not exclude each other as do plasmids, so a strain can accumulate more than one conjugative transposon. Furthermore, there is some evidence that the presence of more than one copy of the conjugative transposon in the strain results in a stimulation of transposition (transactivation) (231). Theoretically, this suggests that as more conjugative transposons with antibiotic resistance genes accumulate in the environment, the transfer of these genes to other bacteria will also increase, and there will be a significant upward spiraling of antibiotic resistance.

Conjugative transposons have been largely responsible for the spread of tetracycline and erythromycin resistance in clinical isolates of *Bacteroides* (250). Fifty years ago, tetracycline resistance was almost nonexistent in this genus (103). By the 1980s a majority of strains were resistant, and today almost all

FIG. 2. Gene arrangement in the *B. fragilis bme5* efflux pump operon and analysis of the *B. fragilis bme5* gene sequences. The *bme* operon codes for the three components of the RND efflux pumps: *bmeA* codes for the linker protein which connects the pump to the outer membrane barrel, *bmeB* codes for the efflux pump, and *bmeC* codes for the outer membrane barrel through which the substance is exported. Most of the *B. fragilis bme* pump operons are in the order (*bmeA-bmeB-bmeC*) but some (e.g., *bmeABC5*, shown here) are different. Another distinctive feature of *bmeABC5* is that it has two promoter regions (indicated by the gold stars). Genomic analysis revealed a putative regulator sequence upstream of *bmeABC*5 (*bmeR*5). We demonstrated that the BmeR5 protein binds to the first intergenic region (IT1) but not to the second or third intergenic region (IT2 or IT3). A closer analysis of IT1 revealed that it had two inverted repeats (IR) (GGGAAT******ATTCCC) separated by six nucleotides. We analyzed a clinical metronidazole-resistant isolate of *B. fragilis* and found a G→T mutation in the IT1 region. Gel shift assays demonstrated that BmeR5 was no longer able to bind to this region.

strains are resistant. Given the potentially rapid increase in resistance rates, the importance of this mode of antibiotic gene transfer can hardly be overstated.

Many of the *Bacteroides* transposons carry the *tetQ* gene and thus confer tetracycline resistance. Further, self-transfer and other activities are significantly stimulated by low levels of tetracycline, regulated by the *tetQ-rteA-rteB* operon (230). Tetracycline increases transcription of *rteA* and -*B*, which code for the sensor and activator components of a two-component regulatory system (discussed above). In turn, RteB activates expression of *rteC*, which is necessary for self-transfer (231).

Mobilizable transposons. Mobilizable transposons, like mobilizable plasmids, cannot self-transfer but can transfer between species in the presence of the TcR helper element (254). The most commonly discussed *Bacteroides* transposons of this class include Tn*4399*, Tn*4555*, and the nonreplicating *Bacteroides* units. The mobilizable transposon Tn*4555*, for example, was first detected during studies of transmissible cefoxitin resistance in a clinical isolate of *Bacteroides vulgatus* (182).

Multidrug Resistance

Data from other gram-negative bacteria, including *P. aeruginosa*, have shown that RND efflux systems can be a major cause of clinically relevant multidrug resistance (191). In contrast, very little is known about efflux pumps in anaerobic bacteria. We described 16 homologs of RND pumps in *Bacteroides fragilis* (284), and there are two reports indirectly implicating efflux pumps in *B. fragilis* in antimicrobial resistance, including resistance to norfloxacin (160, 213); also, a MATE-type efflux system has been characterized in *B. thetaiotaomicron* (161).

RND efflux systems in *B. fragilis*. We identified 16 RND family efflux pumps in *B. fragilis*; we named these *bmeABC1* to -*16* (*B. fragilis m*ultidrug *e*fflux) (284). This system differs from the RND pump system of *P. aeruginosa* in several respects: (i) each operon has all three components (which was not seen in the *Pseudomonas* RND pumps [also known as the Mex system

pumps]); (ii) the *bmeC10* outer membrane component is part of a contiguous gene with the *bmeB10* pump gene; (iii) there are two functional pump genes (*bmeB11* and *bmeB11'*) which are transcribed separately in *bme11*; and (iv) at least 15 of the 16 genes are transcribed (200), whereas in *Pseudomonas* a few of the pumps are transcribed, one or two more may be induced, and the others are normally silent.

Characterization of *bmeB* gene function. In one of our initial experiments exploring *bmeB* gene function, *bme3* was expressed in a hypersusceptible strain of *E. coli* and resulted in higher MICs of several antimicrobial agents (284). Analysis of mutants with deletions of several of the pump genes (MIC patterns coupled with quantitative analysis of their transcription levels) demonstrated that these efflux systems transport a variety of antimicrobial agents (antibiotics, detergents, dyes, and biocides), have overlapping substrate profiles, and confer intrinsic resistance. Deleting three or more efflux pump genes resulted in overexpression of others pumps, possibly as a compensatory response by the bacterium (200). This increased overexpression of some of these efflux pumps caused an increase in MICs of different antimicrobial agents; these increases could be reversed by the addition of broad-spectrum efflux pump inhibitor compounds such as carbonyl cyanide *m*-chlorophenylhydrazone, reserpine, MC-207110, and verapamil. The data strongly suggest a complex regulatory feedback system simultaneously involving multiple pumps.

Selection of multidrug-resistant mutants. We used a variety of antimicrobial agents, including therapeutic choice drugs, to select for multidrug-resistant mutants of *B. fragilis* (196). We selected mutants from both from a laboratory strain and a series of single, double, triple, and quadruple efflux pump deletants. We used a total of 21 agents (antimicrobials, detergents, and dyes) and were able to obtain mutants using cefoxitin, doripenem, imipenem, metronidazole, levofloxacin, and SDS. The mutants selected by these agents exhibited multidrug resistance to unrelated classes of antimicrobial agents. Ten of the 16 *bme* efflux pump genes were overexpressed in one or

TABLE 4. *Bacteroides*: the good and the bad

Characteristic

Beneficial effects associated with *Bacteroides*
  Starch utilizations systems to break down complex polysaccharides
  Zwitterionic polysaccharide mediates T-cell activation
  Aids in development of GALT and a mature immune system
  Directs Paneth cells to produce antibacterial molecules, including
    defensins and lectins
  Deters colonization of the GI tract by pathogens
  May aid in properly development of immune tolerance and
    avoidance of allergy and asthma
  May have a role in preventing obesity

***Bacteroides* as pathogens**
  Can be involved in:
    Infection after colonic contamination of the abdominal cavity
      and tissues
    Bacteremia
    Skin and soft tissue infections
    Osteomyelitis
  May produce enterotoxin and cause GI illness
  Produces hemolysins, histolytic enzymes that cause tissue
    destruction
  May be implicated in Crohn's disease and other IBDs
  Causes abscess formation

more mutants, strongly suggesting that *bmeB* overexpression is a major mechanism of multidrug resistance in *B. fragilis*. The implications of this study corroborate the alarms raised about the overuse of antibiotics and even biocides and demonstrate that exposure to a wide variety of agents can result in multidrug-resistant strains overexpressing multiple efflux pumps. We are currently testing a wide variety of antimicrobial agents, commonly used biocides, and homeopathic "antibacterial" treatments to determine their effect on inducing multidrug resistance (unpublished data).

Multidrug resistance in clinical isolates. Wareham et al. (290) reported the isolation of a *B. fragilis* strain from a patient with anaerobic sepsis. The strain was simultaneously resistant to metronidazole, β-lactams, β-lactam/β-lactamase inhibitor combinations, carbapenems, macrolides, and tetracyclines. Although microbiological cure was apparently achieved with linezolid (an oxazolidinone antibiotic), the patient ultimately succumbed to ischemic bowel disease and died.

We studied this isolate and tested it for the presence and expression of genes associated with a variety of resistance mechanisms (201). In addition to the standard 5.31-Mbp chromosome, WI1 possessed a 16-kb low copy-number native plas-


FIG. 3. Cartoon depiction of the salient features of a theoretical composite of *Bacteroides fragilis* and *Bacteroides thetaiotaomicron* that underscores the extent of its interaction with its environment. (A) Tetracycline has a stimulatory effect on expression of the RteA-RteB two-component regulatory system and induces expression and transfer of tetracycline resistance. The RteA-RteB two-component system controls the expression of a third regulatory gene, *rteC*, which, in turn controls excision and transfer of CTnDot, a conjugative transposon carrying the tetracycline resistance gene (*tetQ*). CTnDot can then transfer *tetQ* to other bacteria. (B and C) ECF-type σ-factor and its membrane-tethered cognate anti-σ-factor. These factors are frequently associated with operons for starch utilization and may be involved in the adaptive ability of *B. thetaiotomicron* to express different enzymes according to specific nutrient availability. (D) ETBF can excrete an endotoxin implicated in GI illness and possibly IBD. (E) *B. fragilis* may resist antimicrobial action in a number of ways. Two of these mechanisms are periplasmic β-lactamase enzymes that digest β-lactamases (and, depending on the enzyme, carbapenems). Another mechanism is the RND-type efflux pumps, which can expel the antibiotic and may contribute to multiple antimicrobial resistance. (F) A hybrid two-component signal system interprets the nutrient environment and may also be involved in sensing the neighboring polysaccharide landscape and modulating "mimicry" so that the surface polysaccharide structure of the bacterium can be altered to match the surrounding landscape. This may allow the bacterium to avoid eliciting a host immune response. (G) The capsule of *B. fragilis* can induce abscesses in the host. Somewhat ironically, the zwitterionic nature of the capsule allows it to "dock" on a groove on the APC and be presented to the CD4+ T cell, which then produces a number of cytokines, including IL-10, which can inhibit abscess formation in the host. (H) Expression of the *bmeB* RND pumps in *B. fragilis* can be induced by a variety of agents, including bile, antimicrobial agents, cleansers, and autoinducers important in quorum sensing among bacteria.

mid, pBHag, which was absent in the *B. fragilis* type strain; sequencing of this plasmid revealed that this plasmid contained the gene for *tetQ* as well as a number of genes that normally reside on the conjugative transposon CTn*341*. Failed curing attempts suggested that it was stable without obvious selection. We found that the *cfiA*, *ermF*, *tetQ2*, and *tetQ3* genes were expressed in the total cellular RNA; neither *tetX* nor *nim* genes were detected. Sequencing of the *gyrA* quinolone resistance-determining region revealed a mutation causing a Ser83→Ile substitution. The efflux pump genes *bmeB9* and *bmeB15* were significantly overexpressed, and addition of efflux pump inhibitors significantly increased susceptibility of the isolate to several unrelated antibiotics. These data suggest that this isolate was highly multidrug resistant due to additive effects of chromosomally and plasmid-encoded resistance determinants.

We also studied recent multidrug-resistant clinical isolates and found that they overexpressed several *bmeB* efflux pumps. The data suggest that *bmeB* efflux pump overexpression can cause low- to intermediate-level clinically relevant fluoroquinolone resistance and can contribute to high-level clinically relevant resistance to β-lactams; moreover, it can be coupled with GyrA substitutions to cause high-level fluoroquinolone resistance (194).

We demonstrated that *bmeB5* was overexpressed in metronidazole-resistant laboratory mutants of *Bacteroides fragilis*, and we identified an upstream putative TetR family regulator gene (*bmeR5*). Deletant strains lacking *bmeB5* or *bmeR5* were constructed and characterized. The MICs of ampicillin, cefoperazone, metronidazole, and SDS were reduced by approximately twofold in ADB77 Δ*bmeB5*. Deletion of *bmeR5* (ADB77 Δ*bmeR5*) resulted in a significant ($P < 0.05$) increase in expression of *bmeA5*, *bmeB5*, and *bmeC5* and a >2-fold increase in MICs of ampicillin, cefoxitin, cefoperazone, ciprofloxacin, imipenem, metronidazole, ethidium bromide, and SDS. We found that BmeR5-His$_6$ bound specifically to the *bmeR5-bmeA5* intergenic region (IT1). A multidrug (metronidazole)-resistant, *nim*-negative *B. fragilis* clinical isolate overexpressed *bmeABC5* genes, had a G-T point mutation in IT1, and significantly reduced binding to BmeR5-His$_6$ (195). A schematic description of *bmeRABC5* is depicted in Fig. 2.

IMPORTANT FUTURE RESEARCH AVENUES

With the adaptability of a chameleon, the *Bacteroides* species can function as an integral partner in the human metabolic system and yet can be the cause of serious, life-threatening disease (Table 4). A cartoon description of the some of the most interesting features of a theoretical composite strain of *B. fragilis* and *B. distasonis* is depicted in Fig. 3. Despite its predominance as the most numerous organism in the human host, progress in understanding *Bacteroides* has consistently lagged behind that for aerobic bacteria. However, with the publication of the genome sequences of *B. fragilis* and *B. thetaiotaomicron*, several tantalizing potential avenues of research are now within reach. Constructing microarrays for *Bacteroides* to measure expression of various genes would be a major step toward unraveling some of the complex regulatory relationships found in this organism. For example, the regulation of efflux pump expression appears to be an important factor in multidrug resistance. The multiplicity of the pumps, coupled with their

overlapping substrate profiles, suggests that inhibiting their action may need to happen at a regulatory level. These efflux pumps may also be involved in the ability of the organism to thrive in the GI tract. Maintaining the proper balance of GI microbes has been long recognized as an important mechanism to avoid colonization by dangerous pathogens; it is now also recognized as a potentially important factor in obesity. A recent report suggested that understanding the manner by which bacteria adapt to specific niches may aid in designing site-directed bacterial vehicles for delivering beneficial molecules to the human GI tract (90). Happily, many of these long-range research goals appear to be intertwined: efflux pumps that affect antimicrobial resistance may be involved in virulence and adhesion, sugar-acquiring pathways and metabolism that allow adaptation to factors in the GI tract may be important in obesity control, and understanding the regulatory factors responsible for controlling the complex face of the *Bacteroides* outer membrane may ultimately allow manipulation to reduce resistance and pathogenicity and to exploit its particular characteristics for beneficial purposes.

REFERENCES

1. **Abi, K. G., H. Awada, and R. Nasnas.** 2001. Isolated septic arthritis of a lumbar facet joint. J. Med. Liban. **49:**228–230.
2. **Anderson, K. L., and A. A. Salyers.** 1989. Genetic evidence that outer membrane binding of starch is required for starch utilization by *Bacteroides thetaiotaomicron.* J. Bacteriol. **171:**3199–3204.
3. **Anderson, K. L., and A. A. Salyers.** 1989. Biochemical evidence that starch breakdown by *Bacteroides thetaiotaomicron* involves outer membrane starch-binding sites and periplasmic starch-degrading enzymes. J. Bacteriol. **171:**3192–3198.
4. **Aucher, P., J. P. Saunier, G. Grollier, M. Sebald, and J. L. Fauchere.** 1996. Meningitis due to enterotoxigenic *Bacteroides fragilis.* Eur. J. Clin. Microbiol. Infect. Dis. **15:**820–823.
5. **Avelar, K. E., L. J. Pinto, L. C. Antunes, L. A. Lobo, M. C. Bastos, R. M. Domingues, and M. C. Ferreira.** 1999. Production of bacteriocin by *Bacteriodes fragilis* and partial characterization. Lett. Appl. Microbiol. **29:**264–268.
6. **Ayala, J., A. Quesada, S. Vadillo, J. Criado, and S. Piriz.** 2005. Penicillin-binding proteins of *Bacteroides fragilis* and their role in the resistance to imipenem of clinical isolates. J. Med. Microbiol. **54:**1055–1064.
7. **Babu, M. M., M. L. Priya, A. T. Selvan, M. Madera, J. Gough, L. Aravind, and K. Sankaran.** 2006. A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins. J. Bacteriol. **188:**2761–2773.
8. **Backhed, F., R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon.** 2005. Host-bacterial mutualism in the human intestine. Science **307:**1915–1920.
9. **Bajzer, M., and R. J. Seeley.** 2006. Physiology: obesity and gut flora. Nature **444:**1009–1010.
10. **Bamba, T., H. Matsuda, M. Endo, and Y. Fujiyama.** 1995. The pathogenic role of *Bacteroides vulgatus* in patients with ulcerative colitis. J. Gastroenterol. **30**(Suppl. 8):45–47.
11. **Bamias, G., A. Okazawa, J. Rivera-Nieves, K. O. Arseneau, S. A. De La Rue, T. T. Pizarro, and F. Cominelli.** 2007. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J. Immunol. **178:**1809–1818.
12. **Basset, C., J. Holton, A. Bazeos, D. Vaira, and S. Bloom.** 2004. Are *Helicobacter* species and enterotoxigenic *Bacteroides fragilis* involved in inflammatory bowel disease? Dig. Dis. Sci. **49:**1425–1432.
13. **Baughn, A. D., and M. H. Malamy.** 2004. The strict anaerobe *Bacteroides fragilis* grows in and benefits from nanomolar concentrations of oxygen. Nature **427:**441–444.
14. **Baumann, H., A. O. Tzianabos, J. R. Brisson, D. L. Kasper, and H. J. Jennings.** 1992. Structural elucidation of two capsular polysaccharides from one strain of *Bacteroides fragilis* using high-resolution NMR spectroscopy. Biochemistry **31:**4081–4089.
15. **Beena, V. K., and P. G. Shivananda.** 1997. In vitro adhesiveness of *Bacte-*

roides fragilis group in relation to encapsulation. Indian J. Med. Res. **105:** 258–261.

16. **Begley, M., C. G. Gahan, and C. Hill.** 2005. The interaction between bacteria and bile. FEMS Microbiol. Rev. **29:**625–651.

17. **Begley, M., C. Hill, and C. G. Gahan.** 2006. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. **72:**1729–1738.

18. **Behra-Miellet, J., L. Calvet, and L. Dubreuil.** 2004. A *Bacteroides thetaiotaomicron* porin that could take part in resistance to beta-lactams. Int. J. Antimicrob. Agents **24:**135–143.

19. **Behra-Miellet, J., L. Calvet, F. Mory, C. Muller, M. Chomarat, M. C. Bezian, S. Bland, M. E. Juvenin, T. Fosse, F. Goldstein, B. Jaulhac, and L. Dubreuil.** 2003. Antibiotic resistance among anaerobic Gram-negative bacilli: lessons from a French multicentric survey. Anaerobe **9:**105–111.

20. **Bendtsen, J. D., T. T. Binnewies, P. F. Hallin, T. Sicheritz-Ponten, and D. W. Ussery.** 2005. Genome update: prediction of secreted proteins in 225 bacterial proteomes. Microbiology **151:**1725–1727.

21. **Bennion, R. S., E. J. Baron, J. E. Thompson, Jr., J. Downes, P. Summanen, D. A. Talan, and S. M. Finegold.** 1990. The bacteriology of gangrenous and perforated appendicitis—revisited. Ann. Surg. **211:**165–171.

22. **Berg, J. O., L. Lindqvist, G. Andersson, and C. E. Nord.** 1983. Neuraminidase in *Bacteroides fragilis*. Appl. Environ. Microbiol. **46:**75–80.

23. **Bergan, T.** 1983. Anaerobic bacteria as cause of infections in female genital organs. Scand. J. Gastroenterol. Suppl. **85:**37–47.

24. **Betriu, C., E. Culebras, M. Gomez, I. Rodriguez-Avial, and J. J. Picazo.** 2005. In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother. **56:**349–352.

25. **Betriu, C., I. Rodriguez-Avial, M. Gomez, E. Culebras, and J. J. Picazo.** 2005. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997–2002). Diagn. Microbiol. Infect. Dis. **53:**221–223.

26. **Bisharat, N., L. Goldstein, R. Raz, and M. Elias.** 2001. Gram-negative anaerobic endocarditis: two case reports and review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. **20:**651–654.

27. **Bjursell, M. K., E. C. Martens, and J. I. Gordon.** 2006. Functional genomic and metabolic studies of the adaptations of a prominent adult human gut symbiont, Bacteroides thetaiotaomicron, to the suckling period. J. Biol. Chem. **281:**36269–36279.

28. **Boquet, P., P. Munro, C. Fiorentini, and I. Just.** 1998. Toxins from anaerobic bacteria: specificity and molecular mechanisms of action. Curr. Opin. Microbiol. **1:**66–74.

29. **Borer, A., G. Weber, K. Riesenberg, F. Schlaeffer, and J. Horowitz.** 1997. Septic arthritis due to *Bacteroides fragilis* after pilonidal sinus resection in a patient with rheumatoid arthritis. Clin. Rheumatol. **16:**632–634.

30. **Brazier, J. S., S. L. Stubbs, and B. I. Duerden.** 1999. Metronidazole resistance among clinical isolates belonging to the *Bacteroides fragilis* group: time to be concerned? J. Antimicrob. Chemother. **44:**580–581. (Letter.)

31. **Brigham, C. J., and M. H. Malamy.** 2005. Characterization of the RokA and HexA broad-substrate-specificity hexokinases from *Bacteroides fragilis* and their role in hexose and *N*-acetylglucosamine utilization. J. Bacteriol. **187:**890–901.

32. **Brioukhanov, A. L., and A. I. Netrusov.** 2004. Catalase and superoxide dismutase: distribution, properties, and physiological role in cells of strict anaerobes. Biochemistry (Moscow) **69:**949–962.

33. **Britz, M. L., and R. G. Wilkinson.** 1978. Chloramphenicol acetyl-transferase of *Bacteroides fragilis*. Antimicrob. Agents Chemother. **14:**105–111.

34. **Bron, P. A., M. Marco, S. M. Hoffer, M. E. Van, W. M. de Vos, and M. Kleerebezem.** 2004. Genetic characterization of the bile salt response in *Lactobacillus plantarum* and analysis of responsive promoters in vitro and in situ in the gastrointestinal tract. J. Bacteriol. **186:**7829–7835.

35. **Brook, I.** 2002. Anaerobic infections in children. Microbes. Infect. **4:**1271–1280.

36. **Brook, I.** 2002. Joint and bone infections due to anaerobic bacteria in children. Pediatr. Rehabil. **5:**11–19.

37. **Brook, I.** 2002. Microbiology and management of post-surgical wounds infection in children. Pediatr. Rehabil. **5:**171–176.

38. **Brook, I.** 2003. Microbiology and management of intra-abdominal infections in children. Pediatr. Int. **45:**123–129.

39. **Brook, I.** 2004. Intra-abdominal, retroperitoneal, and visceral abscesses in children. Eur. J. Pediatr. Surg. **14:**265–273.

40. **Brook, I.** 2002. Pericarditis due to anaerobic bacteria. Cardiology **97:**55–58.

41. **Brook, I.** 2002. Microbiology of polymicrobial abscesses and implications for therapy. J. Antimicrob. Chemother. **50:**805–810.

42. **Brook, I.** 2002. Endocarditis due to anaerobic bacteria. Cardiology **98:**1–5.

43. Reference deleted.

44. **Brook, I.** 2002. Clinical review: bacteremia caused by anaerobic bacteria in children. Crit. Care **6:**205–211.

45. **Brook, I.** 1989. Aerobic and anaerobic microbiology of Bartholin's abscess. Surg. Gynecol. Obstet. **169:**32–34.

46. **Brook, I.** 1986. Anaerobic osteomyelitis in children. Pediatr. Infect. Dis. **5:**550–556.

47. **Brook, I.** 1990. Bacteremia due to anaerobic bacteria in newborns. J. Perinatol. **10:**351–356.

48. **Brook, I., J. C. Coolbaugh, and R. I. Walker.** 1984. Pathogenicity of piliated and encapsulated *Bacteroides fragilis*. Eur. J. Clin. Microbiol. **3:**207–209.

49. **Brook, I., and E. H. Frazier.** 1992. Microbiology of scalp abscess in newborns. Pediatr. Infect. Dis. J. **11:**766–768.

50. **Brook, I., N. Johnson, G. D. Overturf, and J. Wilkins.** 1977. Mixed bacterial meningitis: a complication of ventriculo- and lumboperitoneal shunts. J. Neurosurg. **47:**961–964.

51. **Brook, I., and M. L. Myhal.** 1991. Adherence of *Bacteroides fragilis* group species. Infect. Immun. **59:**742–744.

52. **Bryan, L. E., S. K. Kowand, and H. M. Van Den Elzen.** 1979. Mechanism of aminoglycoside antibiotic resistance in anaerobic bacteria: *Clostridium perfringens* and *Bacteroides fragilis*. Antimicrob. Agents Chemother. **15:**7–13.

53. **Cash, H. L., C. V. Whitham, C. L. Behrendt, and L. V. Hooper.** 2006. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science **313:**1126–1130.

54. **Cerdeno-Tarraga, A. M., S. Patrick, L. C. Crossman, G. Blakely, V. Abratt, N. Lennard, I. Poxton, B. Duerden, B. Harris, M. A. Quail, A. Barron, L. Clark, C. Corton, J. Doggett, M. T. Holden, N. Larke, A. Line, A. Lord, H. Norbertczak, D. Ormond, C. Price, E. Rabbinowitsch, J. Woodward, B. Barrell, and J. Parkhill.** 2005. Extensive DNA inversions in the *B. fragilis* genome control variable gene expression. Science **307:**1463–1465.

55. Reference deleted.

56. **Chaudhry, R., P. Mathur, B. Dhawan, and L. Kumar.** 2001. Emergence of metronidazole-resistant *Bacteroides fragilis*, India. Emerg. Infect. Dis. **7:**485–486. (Letter.)

57. **Chen, Y., T. Kinouchi, K. Kataoka, S. Akimoto, and Y. Ohnishi.** 1995. Purification and characterization of a fibrinogen-degrading protease in *Bacteroides fragilis* strain YCH46. Microbiol. Immunol. **39:**967–977.

58. **Cho, K. H., D. Cho, G. R. Wang, and A. A. Salyers.** 2001. New regulatory gene that contributes to control of *Bacteroides thetaiotaomicron* starch utilization genes. J. Bacteriol. **183:**7198–7205.

59. **Cho, K. H., and A. A. Salyers.** 2001. Biochemical analysis of interactions between outer membrane proteins that contribute to starch utilization by *Bacteroides thetaiotaomicron*. J. Bacteriol. **183:**7224–7230.

60. **Cisneros, J. M., J. Rodriguez-Bano, F. Fernandez-Cuenca, A. Ribera, J. Vila, A. Pascual, L. Martinez-Martinez, G. Bou, and J. Pachon.** 2005. Risk-factors for the acquisition of imipenem-resistant *Acinetobacter baumannii* in Spain: a nationwide study. Clin. Microbiol. Infect. **11:**874–879.

61. **Claros, M. C., Z. C. Claros, D. W. Hecht, D. M. Citron, E. J. Goldstein, J. Silva, Jr., Y. Tang-Feldman, and A. C. Rodloff.** 2006. Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates. Anaerobe **12:**17–22.

62. **Claros, M. C., Z. C. Claros, Y. J. Tang, S. H. Cohen, J. Silva, Jr., E. J. Goldstein, and A. C. Rodloff.** 2000. Occurrence of *Bacteroides fragilis* enterotoxin gene-carrying strains in Germany and the United States. J. Clin. Microbiol. **38:**1996–1997.

63. **Clinical and Laboratory Standards Institute.** 2006. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

64. **Cohavy, O., D. Bruckner, L. K. Gordon, R. Misra, B. Wei, M. E. Eggena, S. R. Targan, and J. Braun.** 2000. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immun. **68:**1542–1548.

65. **Comstock, L. E., and M. J. Coyne.** 2003. *Bacteroides thetaiotaomicron*: a dynamic, niche-adapted human symbiont. Bioessays **25:**926–929.

66. **Corzo, G., and S. E. Gilliland.** 1999. Measurement of bile salt hydrolase activity from *Lactobacillus acidophilus* based on disappearance of conjugated bile salts. J. Dairy Sci. **82:**466–471.

67. **Coyne, M. J., W. Kalka-Moll, A. O. Tzianabos, D. L. Kasper, and L. E. Comstock.** 2000. *Bacteroides fragilis* NCTC9343 produces at least three distinct capsular polysaccharides: cloning, characterization, and reassignment of polysaccharide B and C biosynthesis loci. Infect. Immun. **68:**6176–6181.

68. **Coyne, M. J., B. Reinap, M. M. Lee, and L. E. Comstock.** 2005. Human symbionts use a host-like pathway for surface fucosylation. Science **307:** 1778–1781.

69. **Coyne, M. J., K. G. Weinacht, C. M. Krinos, and L. E. Comstock.** 2003. Mpi recombinase globally modulates the surface architecture of a human commensal bacterium. Proc. Natl. Acad. Sci. USA **100:**10446–10451.

70. **De Boever, P., and W. Verstraete.** 1999. Bile salt deconjugation by *Lactobacillus plantarum* 80 and its implication for bacterial toxicity. J. Appl. Microbiol. **87:**345–352.

71. **Delahooke, D. M., G. R. Barclay, and I. R. Poxton.** 1995. A re-appraisal of the biological activity of bacteroides [sic] LPS. J. Med. Microbiol. **42:**102–112.

72. **D'Elia, J. N., and A. A. Salyers.** 1996. Contribution of a neopullulanase, a pullulanase, and an alpha-glucosidase to growth of *Bacteroides thetaiotaomicron* on starch. J. Bacteriol. **178:**7173–7179.

73. **D'Elia, J. N., and A. A. Salyers.** 1996. Effect of regulatory protein levels on utilization of starch by *Bacteroides thetaiotaomicron*. J. Bacteriol. **178:**7180–7186.

74. **de O. Ferreira, E., L. Araujo Lobo, D. Barreiros Petropolis, K. dos S. Avelar, M. C. Ferreira, F. Costa e Silva Filho, and R. M. Domingues.** 2006.

A *Bacteroides fragilis* surface glycoprotein mediates the interaction between the bacterium and the extracellular matrix component laminin-1. Res. Microbiol. **157:**960–966.

75. **Diniz, C. G., L. M. Farias, M. A. Carvalho, E. R. Rocha, and C. J. Smith.** 2004. Differential gene expression in a *Bacteroides fragilis* metronidazole-resistant mutant. J. Antimicrob. Chemother. **54:**100–108.

76. **Dodd, M. J., I. D. Griffiths, and R. Freeman.** 1982. Pyogenic arthritis due to bacteroides [sic] complicating rheumatoid arthritis. Ann. Rheum. Dis. **41:**248–249.

77. **Domingues, R. M., S. M. Cavalcanti, A. F. Andrade, and M. C. Ferreira.** 1992. Sialic acid as receptor of *Bacteroides fragilis* lectin-like adhesin. Zentbl. Bakteriol. **277:**340–344.

78. **Domingues, R. M., W. das G. Silva e Souza, S. R. Moraes, K. E. Avelar, J. R. Hirata, M. E. Fonseca, and M. C. Ferreira.** 1997. Surface vesicles: a possible function in commensal relations of *Bacteroides fragilis*. Zentbl. Bakteriol. **285:**509–517.

79. **Duncan, S. H., A. Belenguer, G. Holtrop, A. M. Johnstone, H. J. Flint, and G. E. Lobley.** 2007. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ. Microbiol. **73:**1073–1078.

80. **Dutson, T. R., A. M. Pearson, J. F. Price, G. C. Spink, and P. J. Tarrant.** 1971. Observations by electron microscopy on pig muscle inoculated and incubated with *Pseudomonas fragi*. Appl. Microbiol. **22:**1152–1158.

81. **Edmiston, C. E., Jr., C. J. Krepel, K. S. Kehl, G. R. Seabrook, L. B. Somberg, G. H. Almassi, T. L. Smith, T. A. Loehrl, K. R. Brown, B. D. Lewis, and J. B. Towne.** 2005. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J. Antimicrob. Chemother. **56:**872–878.

82. **Edwards, R.** 1997. Resistance to beta-lactam antibiotics in *Bacteroides* spp. J. Med. Microbiol. **46:**979–986.

83. **Edwards, R., and D. Greenwood.** 1996. Mechanisms responsible for reduced susceptibility to imipenem in *Bacteroides fragilis*. J. Antimicrob. Chemother. **38:**941–951.

84. **Elliott, D., J. A. Kufera, and R. A. Myers.** 2000. The microbiology of necrotizing soft tissue infections. Am. J. Surg. **179:**361–366.

85. **Fang, H., C. Edlund, C. E. Nord, and M. Hedberg.** 2002. Selection of cefoxitin-resistant *Bacteroides thetaiotaomicron* mutants and mechanisms involved in β-lactam resistance. Clin. Infect. Dis. **35:**S47–S53.

86. **Fenner, L., V. Roux, M. N. Mallet, and D. Raoult.** 2005. *Bacteroides massiliensis* sp. nov., isolated from blood culture of a newborn. Int. J. Syst. Evol. Microbiol. **55:**1335–1337.

87. **Ferreira, R., M. C. Alexandre, E. N. Antunes, A. T. Pinhao, S. R. Moraes, M. C. Ferreira, and R. M. Domingues.** 1999. Expression of *Bacteroides fragilis* virulence markers in vitro. J. Med. Microbiol. **48:**999–1004.

88. **Feuillet, L., J. Carvajal, I. Sudre, J. Pelletier, J. M. Thomassin, M. Drancourt, and A. A. Cherif.** 2005. First isolation of *Bacteroides thetaiotaomicron* from a patient with a cholesteatoma and experiencing meningitis. J. Clin. Microbiol. **43:**1467–1469.

89. **Fletcher, H. M., and F. L. Macrina.** 1991. Molecular survey of clindamycin and tetracycline resistance determinants in *Bacteroides* species. Antimicrob. Agents Chemother. **35:**2415–2418.

90. **Forum on Microbial Threats.** 2006. Manipulating host-microbe interactions: probiotic research and regulations, p. 207. *In* Ending the war metaphor: the changing agenda for unraveling the host-microbe relationship. The National Academies Press, Washington, DC.

91. **Franco, A. A.** 2004. The *Bacteroides fragilis* pathogenicity island is contained in a putative novel conjugative transposon. J. Bacteriol. **186:**6077–6092.

92. **Franco, A. A., R. K. Cheng, G. T. Chung, S. Wu, H. B. Oh, and C. L. Sears.** 1999. Molecular evolution of the pathogenicity island of enterotoxigenic *Bacteroides fragilis* strains. J. Bacteriol. **181:**6623–6633.

93. **Frank, G. R., and L. G. Rubin.** 1989. Mixed meningitis with *Bacteroides ovatus* caused by an occult congenital dermal sinus. Pediatr. Infect. Dis. J. **8:**401–403.

94. **Freitas, M., E. Tavan, C. Cayuela, L. Diop, C. Sapin, and G. Trugnan.** 2003. Host-pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol. Cell **95:**503–506.

95. **Fujita, H., Y. Eishi, I. Ishige, K. Saitoh, T. Takizawa, T. Arima, and M. Koike.** 2002. Quantitative analysis of bacterial DNA from *Mycobacteria* spp., *Bacteroides vulgatus*, and *Escherichia coli* in tissue samples from patients with inflammatory bowel diseases. J. Gastroenterol. **37:**509–516.

96. **Gal, M., and J. S. Brazier.** 2004. Metronidazole resistance in *Bacteroides* spp. carrying *nim* genes and the selection of slow-growing metronidazole-resistant mutants. J. Antimicrob. Chemother. **54:**109–116.

97. **Ganz, T.** 2000. Paneth cells–guardians of the gut cell hatchery. Nat. Immunol. **1:**99–100.

98. **Gemmell, C. G., P. K. Peterson, D. Schmeling, J. Mathews, and P. G. Quie.** 1983. Antibiotic-induced modification of *Bacteroides fragilis* and its susceptibility to phagocytosis by human polymorphonuclear leukocytes. Eur. J. Clin. Microbiol. **2:**327–334.

99. **Georgopapadakou, N. H., S. A. Smith, and R. B. Sykes.** 1983. Penicillin-binding proteins in *Bacteroides fragilis*. J. Antibiot. (Tokyo) **36:**907–910.

100. **Germain, M., M. A. Krohn, S. L. Hillier, and D. A. Eschenbach.** 1994. Genital flora in pregnancy and its association with intrauterine growth retardation. J. Clin. Microbiol. **32:**2162–2168.

101. **Gibson, S. A., and G. T. Macfarlane.** 1988. Characterization of proteases formed by *Bacteroides fragilis*. J. Gen. Microbiol. **134:**2231–2240.

102. **Gill, S. R., M. Pop, R. T. DeBoy, P. B. Eckburg, P. J. Turnbaugh, B. S. Samuel, J. I. Gordon, D. A. Relman, C. M. Fraser-Liggett, and K. E. Nelson.** 2006. Metagenomic analysis of the human distal gut microbiome. Science **312:**1355–1359.

103. **Gillespie, W. A., and J. Guy.** 1956. *Bacteroides* in intra-abdominal sepsis. Lancet **i:**1039–1041.

104. **Gilmore, M. S., and J. J. Ferretti.** 2003. The thin line between gut commensal and pathogen. Science **299:**1999–2002.

105. **Godoy, V. G., M. M. Dallas, T. A. Russo, and M. H. Malamy.** 1993. A role for *Bacteroides fragilis* neuraminidase in bacterial growth in two model systems. Infect. Immun. **61:**4415–4426.

106. **Goh, B. K., G. Alkouder, T. K. Lama, and C. E. Tan.** 2005. Multi-drug-resistant *Acinetobacter baumannii* intra-abdominal abscess. Surg. Infect. **6:**345–347.

107. **Goldstein, E. J.** 1996. Anaerobic bacteremia. Clin. Infect. Dis. **23**(Suppl. 1)**:**S97–S101.

108. **Gootz, T. D.** 2006. The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance. Biochem. Pharmacol. **71:**1073–1084.

109. **Grenier, D., and D. Mayrand.** 1987. Functional characterization of extracellular vesicles produced by *Bacteroides gingivalis*. Infect. Immun. **55:**111–117.

110. **Guzman, C. A., M. Plate, and C. Pruzzo.** 1990. Role of neuraminidase-dependent adherence of *Bacteroides fragilis* attachment to human epithelial cells. FEMS Microbiol. Lett. **59:**187–192.

111. **Haggoud, A., G. Reysset, H. Azeddoug, and M. Sebald.** 1994. Nucleotide sequence analysis of two 5-nitroimidazole resistance determinants from *Bacteroides* strains and of a new insertion sequence upstream of the two genes. Antimicrob. Agents Chemother. **38:**1047–1051.

112. **Hart, C. A., V. M. Godfrey, J. C. Woodrow, and A. Percival.** 1982. Septic arthritis due to *Bacteroides fragilis* in a wrist affected by rheumatoid arthritis. Ann. Rheum. Dis. **41:**623–624.

113. **Hecht, D. W.** 2006. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe **12:**115–121.

114. **Hecht, D. W.** 2004. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin. Infect. Dis. **39:**92–97.

115. **Hedberg, M., and C. E. Nord.** 2003. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. **9:**475–488.

116. **Heinonen, P. K., and M. Leinonen.** 2003. Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole. Arch. Gynecol. Obstet. **268:**284–288.

117. **Hooper, L. V., and J. I. Gordon.** 2001. Commensal host-bacterial relationships in the gut. Science **292:**1115–1118.

118. **Hooper, L. V., T. Midtvedt, and J. I. Gordon.** 2002. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu. Rev. Nutr. **22:**283–307.

119. **Hooper, L. V., T. S. Stappenbeck, C. V. Hong, and J. I. Gordon.** 2003. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol. **4:**269–273.

120. **Hooper, L. V., M. H. Wong, A. Thelin, L. Hansson, P. G. Falk, and J. I. Gordon.** 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science **291:**881–884.

121. **Hooper, L. V., J. Xu, P. G. Falk, T. Midtvedt, and J. I. Gordon.** 1999. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc. Natl. Acad. Sci. USA **96:**9833–9838.

122. **Hopkins, M. J., and G. T. Macfarlane.** 2002. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J. Med. Microbiol. **51:**448–454.

123. **Hopkins, M. J., and G. T. Macfarlane.** 2003. Nondigestible oligosaccharides enhance bacterial colonization resistance against *Clostridium difficile* in vitro. Appl. Environ. Microbiol. **69:**1920–1927.

124. **Hung, M. N., S. Y. Chen, J. L. Wang, S. C. Chang, P. R. Hsueh, C. H. Liao, and Y. C. Chen.** 2005. Community-acquired anaerobic bacteremia in adults: one-year experience in a medical center. J. Microbiol. Immunol. Infect. **38:**436–443.

125. **Jain, R., and L. H. Danziger.** 2004. Multidrug-resistant *Acinetobacter* infections: an emerging challenge to clinicians. Ann. Pharmacother. **38:**1449–1459.

126. **Johnson, C. C., J. F. Reinhardt, M. A. Edelstein, M. E. Mulligan, W. L. George, and S. M. Finegold.** 1985. *Bacteroides gracilis*, an important anaerobic bacterial pathogen. J. Clin. Microbiol. **22:**799–802.

127. **Jousimies-Somer, H., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold.** 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing Company, Belmont, CA.

128. **Jousimies-Somer, H., P. Summanen, and S. M. Finegold.** 2003. *Bacteroides*, *Porphyromonas*, *Prevotella*, *Fusobacterium* and other anaerobic gram-nega-

tive rods and cocci, p. 690–711. *In* P. R. Murray, E. J. Baron, J. H. P. M. A. Jorgensen, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, DC.

129. **Kalka-Moll, W. M., Y. Wang, L. E. Comstock, S. E. Gonzalez, A. O. Tzianabos, and D. L. Kasper.** 2001. Immunochemical and biological characterization of three capsular polysaccharides from a single *Bacteroides fragilis* strain. Infect. Immun. **69:**2339–2344.

130. **Kanazawa, K., Y. Kobayashi, M. Nakano, M. Sakurai, N. Gotoh, and T. Nishino.** 1995. Identification of three porins in the outer membrane of *Bacteroides fragilis.* FEMS Microbiol. Lett. **127:**181–186.

131. **Kazmierczak, M. J., M. Wiedmann, and K. J. Boor.** 2005. Alternative sigma factors and their roles in bacterial virulence. Microbiol. Mol. Biol. Rev. **69:**527–543.

132. **Khandelwal, P., D. Choudhury, A. Birah, M. K. Reddy, G. P. Gupta, and N. Banerjee.** 2004. Insecticidal pilin subunit from the insect pathogen *Xenorhabdus nematophila.* J. Bacteriol. **186:**6465–6476.

133. **Kim, J. M., J. Y. Lee, Y. M. Yoon, Y. K. Oh, J. S. Kang, Y. J. Kim, and K. H. Kim.** 2006. *Bacteroides fragilis* enterotoxin induces cyclooxygenase-2 and fluid secretion in intestinal epithelial cells through NF-kappaB activation. Eur. J. Immunol. **36:**2446–2456.

134. **Kislak, J. W.** 1972. The susceptibility of *Bacteroides fragilis* to 24 antibiotics. J. Infect. Dis. **125:**295–298.

135. **Kitahara, M., M. Sakamoto, M. Ike, S. Sakata, and Y. Benno.** 2005. *Bacteroides plebeius* sp. nov. and *Bacteroides coprocola* sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. **55:**2143–2147.

136. **Kling, J. J., R. L. Wright, J. S. Moncrief, and T. D. Wilkins.** 1997. Cloning and characterization of the gene for the metalloprotease enterotoxin of *Bacteroides fragilis.* FEMS Microbiol. Lett. **146:**279–284.

137. **Krinos, C. M., M. J. Coyne, K. G. Weinacht, A. O. Tzianabos, D. L. Kasper, and L. E. Comstock.** 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature **414:**555–558.

138. **Kuwahara, T., A. Yamashita, H. Hirakawa, H. Nakayama, H. Toh, N. Okada, S. Kuhara, M. Hattori, T. Hayashi, and Y. Ohnishi.** 2004. Genomic analysis of *Bacteroides fragilis* reveals extensive DNA inversions regulating cell surface adaptation. Proc. Natl. Acad. Sci. USA **101:**14919–14924.

139. **Lassmann, B., D. R. Gustafson, C. M. Wood, and J. E. Rosenblatt.** 2007. Reemergence of anaerobic bacteremia. Clin. Infect. Dis. **44:**895–900.

140. **Leng, Z., D. E. Riley, R. E. Berger, J. N. Krieger, and M. C. Roberts.** 1997. Distribution and mobility of the tetracycline resistance determinant *tetQ.* J. Antimicrob. Chemother. **40:**551–559.

141. **Leszczynski, P., F. Meisel-Mikolajczyk, M. Dworczynska, L. Cwyl-Zembrzuska, and L. Marianowski.** 1995. Occurrence of *Bacteroides fragilis* strains in full term and post term pregnancies. Ginekol. Pol. **66:**324–329.

142. **Leszczynski, P., B. A. Van, H. Pituch, H. Verbrugh, and F. Meisel-Mikolajczyk.** 1997. Vaginal carriage of enterotoxigenic *Bacteroides fragilis* in pregnant women. J. Clin. Microbiol. **35:**2899–2903.

143. **Ley, R. E., F. Backhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight, and J. I. Gordon.** 2005. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA **102:**11070–11075.

144. **Ley, R. E., P. J. Turnbaugh, S. Klein, and J. I. Gordon.** 2006. Microbial ecology: human gut microbes associated with obesity. Nature **444:**1022–1023.

145. **Lindner, J. G., F. H. Plantema, and J. A. Hoogkamp-Korstanje.** 1978. Quantitative studies of the vaginal flora of healthy women and of obstetric and gynaecological patients. J. Med. Microbiol. **11:**233–241.

146. **Liu, C., Y. Song, M. McTeague, A. W. Vu, H. Wexler, and S. M. Finegold.** 2003. Rapid identification of the species of the *Bacteroides fragilis* group by multiplex PCR assays using group- and species-specific primers. FEMS Microbiol. Lett. **222:**9–16.

147. **Livermore, D. M., and N. Woodford.** 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. **3:**489–495.

148. **Lofmark, S., H. Fang, M. Hedberg, and C. Edlund.** 2005. Inducible metronidazole resistance and *nim* genes in clinical *Bacteroides fragilis* group isolates. Antimicrob. Agents Chemother. **49:**1253–1256.

149. **Macfarlane, G. T., S. Macfarlane, and G. R. Gibson.** 1992. Synthesis and release of proteases by *Bacteroides fragilis.* Curr. Microbiol. **24:**55–59.

150. **Mackie, R. I., A. Sghir, and H. R. Gaskins.** 1999. Developmental microbial ecology of the neonatal gastrointestinal tract. Am. J. Clin. Nutr. **69:**1035S–1045S.

151. **Marculescu, C. E., E. F. Berbari, F. R. Cockerill III, and D. R. Osmon.** 2006. Unusual aerobic and anaerobic bacteria associated with prosthetic joint infections. Clin. Orthop. Relat. Res. **451:**55–63.

152. **Martinez-Suarez, J. V., F. Baquero, M. Reig, and J. C. Perez-Diaz.** 1985. Transferable plasmid-linked chloramphenicol acetyltransferase conferring high-level resistance in *Bacteroides uniformis.* Antimicrob. Agents Chemother. **28:**113–117.

153. **Mashburn, L. M., and M. Whiteley.** 2005. Membrane vesicles traffic signals and facilitate group activities in a prokaryote. Nature **437:**422–425.

154. **Mazmanian, S. K., and D. L. Kasper.** 2006. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat. Rev. Immunol. **6:**849–858.

155. **Mazmanian, S. K., C. H. Liu, A. O. Tzianabos, and D. L. Kasper.** 2005. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell **122:**107–118. (Comment.).

156. **McCarthy, R. E., M. Pajeau, and A. A. Salyers.** 1988. Role of starch as a substrate for *Bacteroides vulgatus* growing in the human colon. Appl. Environ. Microbiol. **54:**1911–1916.

157. **Merle-Melet, M., D. Mainard, D. Regent, C. Dopff, J. N. Tamisier, P. Ross, J. P. Delagoutte, and A. Gerard.** 1994. An unusual case of hip septic arthritis due to *Bacteroides fragilis* in an alcoholic patient. Infection **22:**353–355.

158. **Merriam, C. V., H. T. Fernandez, D. M. Citron, K. L. Tyrrell, Y. A. Warren, and E. J. Goldstein.** 2003. Bacteriology of human bite wound infections. Anaerobe **9:**83–86.

159. **Miki, T., T. Kuwahara, H. Nakayama, N. Okada, K. Kataoka, H. Arimochi, and Y. Ohnishi.** 2005. Simultaneous detection of *Bacteroides fragilis* group species by leuB-directed PCR. J. Med. Investig. **52:**101–108.

160. **Miyamae, S., H. Nikaido, Y. Tanaka, and F. Yoshimura.** 1998. Active efflux of norfloxacin by *Bacteroides fragilis.* Antimicrob. Agents Chemother. **42:**2119–2121.

161. **Miyamae, S., O. Ueda, F. Yoshimura, J. Hwang, Y. Tanaka, and H. Nikaido.** 2001. A MATE family multidrug efflux transporter pumps out fluoroquinolones in *Bacteroides thetaiotaomicron.* Antimicrob. Agents Chemother. **45:**3341–3346.

162. **Moncrief, J. S., R. Obiso, Jr., L. A. Barroso, J. J. Kling, R. L. Wright, R. L. Van Tassell, D. M. Lyerly, and T. D. Wilkins.** 1995. The enterotoxin of *Bacteroides fragilis* is a metalloprotease. Infect. Immun. **63:**175–181.

163. **Montejo, B. M., A. P. Gonzalez de Zarate, F. J. Barron, and E. C. Aguirre.** 1984. Meningitis caused by *Bacteroides fragilis.* Can. Med. Assoc. J. **131:**184–186.

164. **Moon, K., N. B. Shoemaker, J. F. Gardner, and A. A. Salyers.** 2005. Regulation of excision genes of the *Bacteroides* conjugative transposon CTnDOT. J. Bacteriol. **187:**5732–5741.

165. **Mossie, K. G., F. T. Robb, D. T. Jones, and D. R. Woods.** 1981. Inhibition of ribonucleic acid polymerase by a bacteriocin from *Bacteroides fragilis.* Antimicrob. Agents Chemother. **20:**437–442.

166. **Nakano, V., G. Padilla, M. M. do Valle, and M. J. Vila-Campos.** 2004. Plasmid-related beta-lactamase production in *Bacteroides fragilis* strains. Res. Microbiol. **155:**843–846.

167. **Namavar, F., M. W. Van der Bijl, B. J. Appelmelk, J. de Graaff, and D. M. Maclaren.** 1994. The role of neuraminidase in haemagglutination and adherence to colon WiDr cells by *Bacteroides fragilis.* J. Med. Microbiol. **40:**393–396.

168. **Ngan, C. C., and A. L. Tan.** 1994. *Bacteroides fragilis* meningitis. Singapore Med. J. **35:**283–285.

169. **Nguyen, M. H., V. L. Yu, A. J. Morris, L. McDermott, M. W. Wagener, L. Harrell, and D. R. Snydman.** 2000. Antimicrobial resistance and clinical outcome of *Bacteroides* bacteremia: findings of a multicenter prospective observational trial. Clin. Infect. Dis. **30:**870–876.

170. **Odou, M. F., E. Singer, and L. Dubreuil.** 2001. Description of complex forms of a porin in *Bacteroides fragilis* and possible implication of this protein in antibiotic resistance. Anaerobe **7:**219–225.

171. **Odou, M. F., E. Singer, M. B. Romond, and L. Dubreuil.** 1998. Isolation and characterization of a porin-like protein of 45 kilodaltons from *Bacteroides fragilis.* FEMS Microbiol. Lett. **166:**347–354.

172. **Odugbemi, T., S. A. Jatto, and K. Afolabi.** 1985. *Bacteroides fragilis* meningitis. J. Clin. Microbiol. **21:**282–283.

173. **Ogawa, W., D. W. Li, P. Yu, A. Begum, T. Mizushima, T. Kuroda, and T. Tsuchiya.** 2005. Multidrug resistance in *Klebsiella pneumoniae* MGH78578 and cloning of genes responsible for the resistance. Biol. Pharm. Bull. **28:**1505–1508.

174. **Oh, H., N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund.** 2001. gyrA mutations associated with quinolone resistance in *Bacteroides fragilis* group strains. Antimicrob. Agents Chemother. **45:**1977–1981.

175. **Osborne, N. G.** 2006. The role of *Bacteroides fragilis* in pelvic infections. J. Gynecol. Surg. **22:**81–82.

176. **Otto, B. R., M. Sparrius, A. M. Verweij-van Vught, and D. M. Maclaren.** 1990. Iron-regulated outer membrane protein of *Bacteroides fragilis* involved in heme uptake. Infect. Immun. **58:**3954–3958.

177. **Oyston, P. C., and P. S. Handley.** 1990. Surface structures, haemagglutination and cell surface hydrophobicity of *Bacteroides fragilis* strains. J. Gen. Microbiol. **136:**941–948.

178. **Oyston, P. C., and P. S. Handley.** 1991. Surface components of *Bacteroides fragilis* involved in adhesion and haemagglutination. J. Med. Microbiol. **34:**51–55.

179. **Pantosti, A., A. O. Tzianabos, A. B. Onderdonk, and D. L. Kasper.** 1991. Immunochemical characterization of two surface polysaccharides of *Bacteroides fragilis.* Infect. Immun. **59:**2075–2082.

180. **Pantosti, A., A. O. Tzianabos, B. G. Reinap, A. B. Onderdonk, and D. L. Kasper.** 1993. *Bacteroides fragilis* strains express multiple capsular polysaccharides. J. Clin. Microbiol. **31:**1850–1855.

181. **Park, J. T.** 2001. Identification of a dedicated recycling pathway for anhydro-*N*-acetylmuramic acid and *N*-acetylglucosamine derived from *Escherichia coli* cell wall murein. J. Bacteriol. **183:**3842–3847.

182. **Parker, A. C., and C. J. Smith.** 1993. Genetic and biochemical analysis of a novel Ambler class A beta-lactamase responsible for cefoxitin resistance in *Bacteroides* species. Antimicrob. Agents Chemother. **37:**1028–1036.

183. **Patey, O., J. Breuil, A. Fisch, C. Burnat, F. Vincent-Ballereau, and A. Dublanchet.** 1990. *Bacteroides fragilis* meningitis: report of two cases. Rev. Infect. Dis. **12:**364–365.

184. **Patrick, S., D. Gilpin, and L. Stevenson.** 1999. Detection of intrastrain antigenic variation of *Bacteroides fragilis* surface polysaccharides by monoclonal antibody labelling. Infect. Immun. **67:**4346–4351.

185. **Patrick, S., J. P. McKenna, S. O'Hagan, and E. Dermott.** 1996. A comparison of the haemagglutinating and enzymic activities of *Bacteroides fragilis* whole cells and outer membrane vesicles. Microb. Pathog. **20:**191–202.

186. **Paulsen, I. T., L. Banerjei, G. S. Myers, K. E. Nelson, R. Seshadri, T. D. Read, D. E. Fouts, J. A. Eisen, S. R. Gill, J. F. Heidelberg, H. Tettelin, R. J. Dodson, L. Umayam, L. Brinkac, M. Beanan, S. Daugherty, R. T. DeBoy, S. Durkin, J. Kolonay, R. Madupu, W. Nelson, J. Vamathevan, B. Tran, J. Upton, T. Hansen, J. Shetty, H. Khouri, T. Utterback, D. Radune, K. A. Ketchum, B. A. Dougherty, and C. M. Fraser.** 2003. Role of mobile DNA in the evolution of vancomycin-resistant *Enterococcus faecalis*. Science **299:**2071–2074.

187. **Piddock, L. J. V., and R. Wise.** 1987. Cefoxitin resistance in *Bacteroides* species: evidence indicating two mechanisms causing decreased susceptibility. J. Antimicrob. Chemother. **19:**161–170.

188. **Piriz, S., S. Vadillo, A. Quesada, J. Criado, R. Cerrato, and J. Ayala.** 2004. Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of *Bacteroides fragilis* with different susceptibility to beta-lactam antibiotics. J. Med. Microbiol. **53:**213–221.

189. **Podglajen, I., J. Breuil, and E. Collatz.** 1994. Insertion of a novel DNA sequence, IS1186, upstream of the silent carbapenemase gene *cfiA*, promotes expression of carbapenem resistance in clinical isolates of *Bacteroides fragilis*. Mol. Microbiol. **12:**105–114.

190. **Polk, B. F., and D. L. Kasper.** 1977. *Bacteroides fragilis* subspecies in clinical isolates. Ann. Intern. Med. **86:**569–571.

191. **Poole, K., and R. Srikumar.** 2001. Multidrug efflux in *Pseudomonas aeruginosa*: components, mechanisms and clinical significance. Curr. Top. Med. Chem. **1:**59–71.

192. **Prindiville, T. P., R. A. Sheikh, S. H. Cohen, Y. J. Tang, M. C. Cantrell, and J. Silva, Jr.** 2000. *Bacteroides fragilis* enterotoxin gene sequences in patients with inflammatory bowel disease. Emerg. Infect. Dis. **6:**171–174.

193. **Pruzzo, C., B. Dainelli, and M. Ricchetti.** 1984. Piliated *Bacteroides fragilis* strains adhere to epithelial cells and are more sensitive to phagocytosis by human neutrophils than nonpiliated strains. Infect. Immun. **43:**189–194.

194. **Pumbwe, L., A. Chang, R. L. Smith, and H. M. Wexler.** 2006. Clinical significance of overexpression of multiple RND-family efflux pumps in *Bacteroides fragilis* isolates. J. Antimicrob. Chemother. **58:**543–548.

195. **Pumbwe, L., A. Chang, and H. M. Wexler.** 2007. The RND-family transport system BmeRABC-5 is a metronidazole efflux pump in *Bacteroides fragilis*. Microb. Drug Resist. **13:**96–101.

196. **Pumbwe, L., D. Glass, and H. M. Wexler.** 2006. Efflux pump overexpression in multiple antibiotic resistant mutants of *Bacteroides fragilis*. Antimicrob. Agents Chemother. **50:**3150–3153.

197. **Pumbwe, L., C. Skilbeck, A. Oren, and H. M. Wexler.** 2007. Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of *Bacteroides fragilis*. Microb. Pathog. **43:**78–87.

198. **Pumbwe, L., C. Skilbeck, and H. M. Wexler.** Impact of anatomic site on growth, efflux pump expression, cell structure and stress responsiveness of *Bacteroides fragilis*. Curr. Microbiol., in press.

199. **Pumbwe, L., C. A. Skilbeck, and H. M. Wexler.** 2006. The *Bacteroides fragilis* cell envelope: quarterback, linebacker, coach—or all three? Anaerobe **12:**211–220.

200. **Pumbwe, L., O. Ueda, F. Yoshimura, A. Chang, R. Smith, and H. M. Wexler.** 2006. *Bacteroides fragilis* BmeABC efflux systems additively confer intrinsic antimicrobial resistance. J. Antimicrob. Chemother. **58:**37–46.

201. **Pumbwe, L., D. W. Wareham, J. Aduse-Opoku, J. S. Brazier, and H. M. Wexler.** 2007. Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of *Bacteroides fragilis*. Clin. Microbiol. Infect. **13:**183–189.

202. **Ramsay, A. G., K. P. Scott, J. C. Martin, M. T. Rincon, and H. J. Flint.** 2006. Cell-associated alpha-amylases of butyrate-producing Firmicute bacteria from the human colon. Microbiology **152:**3281–3290.

203. **Rasmussen, B. A., K. Bush, and F. P. Tally.** 1993. Antimicrobial resistance in *Bacteroides*. Clin. Infect. Dis. **16**(Suppl. 4):S390–S400.

204. **Rasmussen, B. A., and E. Kovacs.** 1993. Cloning and identification of a two-component signal-transducing regulatory system from *Bacteroides fragilis*. Mol. Microbiol. **7:**765–776.

205. **Rasmussen, J. L., D. A. Odelson, and F. L. Macrina.** 1987. Complete nucleotide sequence of insertion element IS4351 from *Bacteroides fragilis*. J. Bacteriol. **169:**3573–3580.

206. **Reeves, A. R., J. N. D'Elia, J. Frias, and A. A. Salyers.** 1996. A *Bacteroides thetaiotaomicron* outer membrane protein that is essential for utilization of maltooligosaccharides and starch. J. Bacteriol. **178:**823–830.

207. **Reeves, A. R., G. R. Wang, and A. A. Salyers.** 1997. Characterization of four outer membrane proteins that play a role in utilization of starch by *Bacteroides thetaiotaomicron*. J. Bacteriol. **179:**643–649.

208. **Reid, G.** 2004. When microbe meets human. Clin. Infect. Dis. **39:**827–830.

209. **Reid, J. H., and S. Patrick.** 1984. Phagocytic and serum killing of capsulate and non-capsulate *Bacteroides fragilis*. J. Med. Microbiol. **17:**247–257.

210. **Renz, H., N. Blumer, S. Virna, S. Sel, and H. Garn.** 2006. The immunological basis of the hygiene hypothesis. Chem. Immunol. Allergy **91:**30–48.

211. **Reysset, G.** 1996. Genetics of 5-nitroimidazole resistance in *Bacteroides* species. Anaerobe **2:**59–69.

212. **Rhee, K. J., P. Sethupathi, A. Driks, D. K. Lanning, and K. L. Knight.** 2004. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J. Immunol. **172:**1118–1124.

213. **Ricci, V., M. L. Peterson, J. C. Rotschafer, H. Wexler, and L. J. Piddock.** 2004. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of *Bacteroides fragilis* clinical isolates and laboratory mutants. Antimicrob. Agents Chemother. **48:**1344–1346.

214. **Riepe, S. P., J. Goldstein, and D. H. Alpers.** 1980. Effect of secreted *Bacteroides* proteases on human intestinal brush border hydrolases. J. Clin. Investig. **66:**314–322.

215. **Roberts, M. C.** 2003. Acquired tetracycline and/or macrolide-lincosamides-streptogramin resistance in anaerobes. Anaerobe **9:**63–69.

216. **Robertson, K. P., C. J. Smith, A. M. Gough, and E. R. Rocha.** 2006. Characterization of *Bacteroides fragilis* hemolysins and regulation and synergistic interactions of HlyA and HlyB. Infect. Immun. **74:**2304–2316.

217. **Rocha, E. R., T. Selby, J. P. Coleman, and C. J. Smith.** 1996. Oxidative stress response in an anaerobe, *Bacteroides fragilis*: a role for catalase in protection against hydrogen peroxide. J. Bacteriol. **178:**6895–6903.

218. **Rogemond, V., and R. M. Guinet.** 1986. Lectinlike adhesins in the *Bacteroides fragilis* group. Infect. Immun. **53:**99–102.

219. **Rogers, M. B., A. C. Parker, and C. J. Smith.** 1993. Cloning and characterization of the endogenous cephalosporinase gene, *cepA*, from *Bacteroides fragilis* reveals a new subgroup of Ambler class A beta-lactamases. Antimicrob. Agents Chemother. **37:**2391–2400.

220. **Rosenkranz, P., M. M. Lederman, K. V. Gopalakrishna, and J. J. Ellner.** 1990. Septic arthritis caused by *Bacteroides fragilis*. Rev. Infect. Dis. **12:**20–30.

221. **Rotimi, V. O., T. L. Verghese, N. Al-Sweih, F. B. Khodakhast, and K. Ahmed.** 2000. Influence of five antianaerobic antibiotics on endotoxin liberation by gram-negative anaerobes. J. Chemother. **12:**40–47.

222. **Rudek, W., and R. U. Haque.** 1976. Extracellular enzymes of the genus *Bacteroides*. J. Clin. Microbiol. **4:**458–460.

223. **Russo, T. A., J. S. Thompson, V. G. Godoy, and M. H. Malamy.** 1990. Cloning and expression of the Bacteroides fragilis TAL2480 neuraminidase gene, *nanH*, in *Escherichia coli*. J. Bacteriol. **172:**2594–2600.

224. **Sachs, J.** 2005. Are antibiotics killing us? Discover **26:**36.

225. **Sakamoto, M., and Y. Benno.** 2006. Reclassification of *Bacteroides distasonis*, *Bacteroides goldsteinii* and *Bacteroides merdae* as *Parabacteroides distasonis gen.nov*, *comb. nov*., *Parabacteroides goldsteinii comb. nov.* and *Parabacteroides merdae comb. nov.* Int. J. Syst. Bacteriol. **56:**1599–1605.

226. **Salyers, A. A.** 1984. *Bacteroides* of the human lower intestinal tract. Annu. Rev. Microbiol. **38:**293–313.

227. **Salyers, A. A., and C. F. Amabile-Cuevas.** 1997. Why are antibiotic resistance genes so resistant to elimination? Antimicrob. Agents Chemother. **41:**2321–2325.

228. **Salyers, A. A., A. Gupta, and Y. Wang.** 2004. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol. **12:**412–416.

229. **Salyers, A. A., and M. Pajeau.** 1989. Competitiveness of different polysaccharide utilization mutants of *Bacteroides thetaiotaomicron* in the intestinal tracts of germfree mice. Appl. Environ. Microbiol. **55:**2572–2578.

230. **Salyers, A. A., N. B. Shoemaker, and L. Y. Li.** 1995. In the driver's seat: the *Bacteroides* conjugative transposons and the elements they mobilize. J. Bacteriol. **177:**5727–5731.

231. **Salyers, A. A., N. B. Shoemaker, A. M. Stevens, and L. Y. Li.** 1995. Conjugative transposons: an unusual and diverse set of integrated gene transfer elements. Microbiol. Rev. **59:**579–590.

232. **Salyers, A. A., B. S. Speer, and N. B. Shoemaker.** 1990. New perspectives in tetracycline resistance. Mol. Microbiol. **4:**151–156.

233. **Salyers, A. A., P. Valentine, and V. Hwa.** 1993. Genetics of polysaccharide utilization pathways of colonic *Bacteroides* species, p. 505–516. *In* M. Sebald (ed.), Genetics and molecular biology of anaerobic bacteria. Springer-Verlag, New York, NY.

234. **Sanchez, S.** 2006. Where do antimicrobial resistances reside on the farm?, abstr. A-108. Abstr. 105th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.

235. **San Joaquin, V., J. C. Griffis, C. Lee, and C. L. Sears.** 1995. Association of *Bacteroides fragilis* with childhood diarrhea. Scand. J. Infect. Dis. **27:**211–215.

236. **Schapiro, J. M., R. Gupta, E. Stefansson, F. C. Fang, and A. P. Limaye.** 2004. Isolation of metronidazole-resistant *Bacteroides fragilis* carrying the *nimA* nitroreductase gene from a patient in Washington State. J. Clin. Microbiol. **42:**4127–4129.

237. **Schauer, R.** 2004. Sialic acids: fascinating sugars in higher animals and man. Zoology (Jena) **107:**49–64.

238. **Sears, C. L.** 2001. The toxins of *Bacteroides fragilis*. Toxicon **39:**1737–1746.

239. **Senneville, E., C. Savage, I. Nallet, Y. Yazdanpanah, F. Giraud, H. Migaud, L. Dubreuil, R. Courcol, and Y. Mouton.** 2006. Improved aero-anaerobe recovery from infected prosthetic joint samples taken from 72 patients and collected intraoperatively in Rosenow's broth. Acta Orthop. **77:**120–124.

240. **Shah, H. N., and D. M. Collins.** 1990. *Prevotella*, a new genus to include *Bacteroides melaninogenicus* and related species formerly classified in the genus *Bacteroides*. Int. J. Syst. Bacteriol. **40:**205–208.

241. **Shah, H. N., and M. D. Collins.** 1989. Proposal to restrict the genus *Bacteroides* (Castellani and Chalmers) to *Bacteroides fragilis* and closely related species. Int. J. Syst. Bacteriol. **39:**85–87.

242. **Shah, H. N., and M. D. Collins.** 1988. Proposal for reclassfication of *Bacteroides asaccharolyticus*, *Bacteroides gingivalis*, and *Bacteroides endodontalis* in a new genus, *Porphyromonas*. Int. J. Syst. Bacteriol. **38:**128–131.

243. **Shapiro, M. E., D. L. Kasper, D. F. Zaleznik, S. Spriggs, A. B. Onderdonk, and R. W. Finberg.** 1986. Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to *Bacteroides fragilis*. J. Immunol. **137:**341–346.

244. **Shapiro, M. E., A. B. Onderdonk, D. L. Kasper, and R. W. Finberg.** 1982. Cellular immunity to *Bacteroides fragilis* capsular polysaccharide. J. Exp. Med. **155:**1188–1197.

245. **Shapiro, M. E., A. B. Onderdonk, D. L. Kasper, and R. W. Finberg.** 1983. Immune T cells prevent *Bacteroides fragilis* abscesses. Curr. Surg. **40:**123–126.

246. **Shetab, R., S. H. Cohen, T. Prindiville, Y. J. Tang, M. Cantrell, D. Rahmani, and J. Silva, Jr.** 1998. Detection of *Bacteroides fragilis* enterotoxin gene by PCR. J. Clin. Microbiol. **36:**1729–1732.

247. **Shipman, J. A., J. E. Berleman, and A. A. Salyers.** 2000. Characterization of four outer membrane proteins involved in binding starch to the cell surface of *Bacteroides thetaiotaomicron*. J. Bacteriol. **182:**5365–5372.

248. **Shipman, J. A., K. H. Cho, H. A. Siegel, and A. A. Salyers.** 1999. Physiological characterization of SusG, an outer membrane protein essential for starch utilization by *Bacteroides thetaiotaomicron*. J. Bacteriol. **181:**7206–7211.

249. **Shoemaker, N. B., R. D. Barber, and A. A. Salyers.** 1989. Cloning and characterization of a *Bacteroides* conjugal tetracycline-erythromycin resistance element by using a shuttle cosmid vector. J. Bacteriol. **171:**1294–1302.

250. **Shoemaker, N. B., H. Vlamakis, K. Hayes, and A. A. Salyers.** 2001. Evidence for extensive resistance gene transfer among *Bacteroides* spp. and among *Bacteroides* and other genera in the human colon. Appl. Environ. Microbiol. **67:**561–568.

251. **Simon, G. L., and S. L. Gorbach.** 1984. Intestinal flora in health and disease. Gastroenterology **86:**174–193.

252. **Simon, G. L., M. S. Klempner, D. L. Kasper, and S. L. Gorbach.** 1982. Alterations in opsonophagocytic killing by neutrophils of *Bacteroides fragilis* associated with animal and laboratory passage: effect of capsular polysaccharide. J. Infect. Dis. **145:**72–77.

253. **Smalley, D., E. R. Rocha, and C. J. Smith.** 2002. Aerobic-type ribonucleotide reductase in the anaerobe *Bacteroides fragilis*. J. Bacteriol. **184:**895–903.

254. **Smith, C. J., G. D. Tribble, and D. P. Bayley.** 1998. Genetic elements of *Bacteroides* species: a moving story. Plasmid **40:**12–29.

255. **Snyder, D. R., N. V. Jacobus, and L. A. McDermott.** 2005. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. J. Antimicrob. Chemother. **55:**1024–1028.

256. **Snyder, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, Y. Golan, E. J. Goldstein, S. M. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, V. Yu, J. Rihs, and S. L. Gorbach.** 2007. National survey on the susceptibility of *Bacteroides fragilis* group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents Chemother. **51:**1649–1655.

257. **Snyder, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. Goldstein, S. Finegold, L. Harrell, D. W. Hecht, S. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach.** 2002. In vitro activities of newer quinolones against *Bacteroides* group organisms. Antimicrob. Agents Chemother. **46:**3276–3279.

258. **Snyder, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. J. Goldstein, S. M. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach.** 2002. National survey on the susceptibility of *Bacteroides fragilis* group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. **35:**S126–S134.

259. **Soki, J., M. Gal, J. S. Brazier, V. O. Rotimi, E. Urban, E. Nagy, and B. I. Duerden.** 2006. Molecular investigation of genetic elements contributing to metronidazole resistance in *Bacteroides* strains. J. Antimicrob. Chemother. **57:**212–220.

260. **Song, Y., C. Liu, M. Bolanos, J. Lee, M. McTeague, and S. M. Finegold.** 2005. Evaluation of 16S rRNA sequencing and reevaluation of a short biochemical scheme for identification of clinically significant *Bacteroides* species. J. Clin. Microbiol. **43:**1531–1537.

261. **Song, Y., C. Liu, J. Lee, M. Bolanos, M. L. Vaisanen, and S. M. Finegold.** 2005. "*Bacteroides goldsteinii* sp. nov." isolated from clinical specimens of human intestinal origin. J. Clin. Microbiol. **43:**4522–4527.

262. **Song, Y. L., C. X. Liu, M. McTeague, and S. M. Finegold.** 2004. "*Bacteroides nordii*" sp. nov. and "*Bacteroides salyersae*" sp. nov. isolated from clinical specimens of human intestinal origin. J. Clin. Microbiol. **42:**5565–5570.

263. **Sonnenburg, E. D., J. L. Sonnenburg, J. K. Manchester, E. E. Hansen, H. C. Chiang, and J. I. Gordon.** 2006. A hybrid two-component system protein of a prominent human gut symbiont couples glycan sensing in vivo to carbohydrate metabolism. Proc. Natl. Acad. Sci. USA **103:**8834–8839.

264. **Sonnenburg, J. L., L. T. Angenent, and J. I. Gordon.** 2004. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat. Immunol. **5:**569–573.

265. **Sonnenburg, J. L., J. Xu, D. D. Leip, C. H. Chen, B. P. Westover, J. Weatherford, J. D. Buhler, and J. I. Gordon.** 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science **307:**1955–1959.

266. **Stappenbeck, T. S., L. V. Hooper, and J. I. Gordon.** 2002. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. USA **99:**15451–15455.

267. **Stellwag, E. J., and P. B. Hylemon.** 1976. Purification and characterization of bile salt hydrolase from *Bacteroides fragilis* subsp. *fragilis*. Biochim. Biophys. Acta **452:**165–176.

268. **Stock, A. M., V. L. Robinson, and P. N. Goudreau.** 2000. Two-component signal transduction. Annu. Rev. Biochem. **69:**183–215.

269. **Strober, W.** 2006. Unraveling gut inflammation. Science **313:**1052–1054.

270. **Strober, W., I. Fuss, and P. Mannon.** 2007. The fundamental basis of inflammatory bowel disease. J. Clin. Investig. **117:**514–521.

271. **Takeuchi, T., Y. Nakaya, N. Kato, K. Watanabe, and K. Morimoto.** 1999. Induction of oxidative DNA damage in anaerobes. FEBS Lett. **450:**178–180.

272. **Talan, D. A., D. M. Citron, F. M. Abrahamian, G. J. Moran, E. J. Goldstein, et al.** 1999. Bacteriologic analysis of infected dog and cat bites. N. Engl. J. Med. **340:**85–92.

273. **Tally, F. P., G. J. Cuchural, Jr., and M. H. Malamy.** 1984. Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy. Rev. Infect. Dis. **6**(Suppl. 1):S260–S269.

274. **Tanaka, H., F. Ito, and T. Iwasaki.** 1992. Purification and characterization of a sialidase from *Bacteroides fragilis* SBT3182. Biochem. Biophys. Res. Commun. **189:**524–529.

275. **Tanaka, K., H. Mikamo, K. Nakao, and K. Watanabe.** 2006. In vitro anti-anaerobic activity of DX-619, a new des-fluoro(6) quinolone. Antimicrob. Agents Chemother. **50:**3908–3913.

276. **Tancula, E., M. J. Feldhaus, L. A. Bedzyk, and A. A. Salyers.** 1992. Location and characterization of genes involved in binding of starch to the surface of *Bacteroides thetaiotaomicron*. J. Bacteriol. **174:**5609–5616.

277. **Toprak, N. U., A. Yagci, B. M. Gulluoglu, M. L. Akin, P. Demirkalem, T. Celenk, and G. Soyletir.** 2006. A possible role of *Bacteroides fragilis* enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. **12:**782–786.

278. **Trinh, S., A. Haggoud, G. Reysset, and M. Sebald.** 1995. Plasmids pIP419 and pIP421 from *Bacteroides*: 5-nitroimidazole resistance genes and their upstream insertion sequence elements. Microbiology **141:**927–935.

279. **Trinh, S., and G. Reysset.** 1996. Detection by PCR of the *nim* genes encoding 5-nitroimidazole resistance in *Bacteroides* spp. J. Clin. Microbiol. **34:**2078–2084.

280. **Turnbaugh, P. J., R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon.** 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature **444:**1027–1131.

281. **Tzianabos, A. O., D. L. Kasper, and A. B. Onderdonk.** 1995. Structure and function of *Bacteroides fragilis* capsular polysaccharides: relationship to induction and prevention of abscesses. Clin. Infect. Dis. **20**(Suppl. 2):S132–S140.

282. **Tzianabos, A. O., A. B. Onderdonk, B. Rosner, R. L. Cisneros, and D. L. Kasper.** 1993. Structural features of polysaccharides that induce intraabdominal abscesses. Science **262:**416–419.

283. **Tzianabos, A. O., A. Pantosti, H. Baumann, J. R. Brisson, H. J. Jennings, and D. L. Kasper.** 1992. The capsular polysaccharide of *Bacteroides fragilis* comprises two ionically linked polysaccharides. J. Biol. Chem. **267:**18230–18235.

284. **Ueda, O., H. M. Wexler, K. Hirai, Y. Shibata, F. Yoshimura, and S. Fujimura.** 2005. Sixteen homologs of the Mex-type multidrug resistance efflux pump in *Bacteroides fragilis*. Antimicrob. Agents Chemother. **49:**2807–2815.

285. **University of Capetown.** 11 April 2005, posting date. The enemy inside. *In* UCT Online–Monday paper. University of Capetown, Capetown, South Africa. http://www.news.uct.ac.za/mondaypaper/archives/?id=5053.

286. **Vandamme, P., M. I. Daneshvar, F. E. Dewhirst, B. J. Paster, K. Kersters, H. Goossens, and C. W. Moss.** 1995. Chemotaxonomic analyses of *Bacteroides gracilis* and *Bacteroides ureolyticus* and reclassification of *B. gracilis* as *Campylobacter gracilis* comb. nov. Int. J. Syst. Bacteriol. **45:**145–152.

287. **Vieira, J. M., D. C. Vallim, E. O. Ferreira, S. H. Seabra, R. C. Vommaro, K. E. Avelar, S. W. De, M. C. Ferreira, and R. M. Domingues.** 2005.

Bacteroides fragilis interferes with iNOS activity and leads to pore formation in macrophage surface. Biochem. Biophys. Res. Commun. **326:**607–613.

288. **Wang, R. C., S. J. Seror, M. Blight, J. M. Pratt, J. K. Broome-Smith, and I. B. Holland.** 1991. Analysis of the membrane organization of an *Escherichia coli* protein translocator, HlyB, a member of a large family of prokaryote and eukaryote surface transport proteins. J. Mol. Biol. **217:**441–454.

289. **Wang, Y., W. M. Kalka-Moll, M. H. Roehrl, and D. L. Kasper.** 2000. Structural basis of the abscess-modulating polysaccharide A2 from *Bacteroides fragilis*. Proc. Natl. Acad. Sci. USA **97:**13478–13483.

290. **Wareham, D. W., M. Wilks, D. Ahmed, J. S. Brazier, and M. Millar.** 2005. Anaerobic sepsis due to multidrug-resistant *Bacteroides fragilis*: microbiological cure and clinical response with linezolid therapy. Clin. Infect. Dis. **40:**e67–e68.

291. **Weintraub, A., B. E. Larsson, and A. A. Lindberg.** 1985. Chemical and immunochemical analyses of *Bacteroides fragilis* lipopolysaccharides. Infect. Immun. **49:**197–201.

292. **Weiser, J. N., and E. C. Gotschlich.** 1991. Outer membrane protein A (OmpA) contributes to serum resistance and pathogenicity of *Escherichia coli* K-1. Infect. Immun. **59:**2252–2258.

293. **Weiss, S. T.** 2002. Eat dirt: the hygiene hypothesis and allergic diseases. N. Engl. J. Med. **347:**930–931.

294. **Welch, R. A., K. R. Jones, and F. L. Macrina.** 1979. Transferable lincosamide-macrolide resistance in *Bacteroides*. Plasmid **2:**261–268.

295. **Wells, C. L., M. A. Maddaus, R. P. Jechorek, and R. L. Simmons.** 1988. Role of intestinal anaerobic bacteria in colonization resistance. Eur. J. Clin. Microbiol. Infect. Dis. **7:**107–113.

296. **Wexler, H. M., A. E. Engel, D. Glass, and C. Li.** 2005. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. **49:**4413–4417.

297. **Wexler, H. M., C. Getty, and G. Fisher.** 1992. The isolation and characterisation of a major outer-membrane protein from *Bacteroides distasonis*. J. Med. Microbiol. **37:**165–175.

298. **Wexler, H. M., and S. Halebian.** 1990. Alterations to the penicillin-binding proteins in the *Bacteroides fragilis* group: a mechanism for non-β-lactamase mediated cefoxitin resistance. J. Antimicrob. Chemother. **26:**7–20.

299. **Wexler, H. M., E. Molitoris, D. Molitoris, and S. M. Finegold.** 1998. In vitro activity of levofloxacin against a selected group of anaerobic bacteria iso-lated from skin and soft tissue infections. Antimicrob. Agents Chemother. **42:**984–986.

300. **Wexler, H. M., E. Molitoris, D. Reeves, and S. M. Finegold.** 1994. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob. Agents Chemother. **38:**2504–2509.

301. **Wexler, H. M., E. K. Read, and T. J. Tomzynski.** 2002. Characterization of *omp200*, a porin gene complex from *Bacteroides fragilis*: *omp121* and *omp71*, gene sequence, deduced amino acid sequence and predictions of porin structure. Gene **283:**95–105.

302. **Wexler, H. M., E. K. Read, and T. J. Tomzynski.** 2002. Identification of an OmpA protein from *Bacteroides fragilis*: *ompA* gene sequence, OmpA amino acid sequence and predictions of protein structure. Anaerobe **8:**180–191.

303. **Wu, S., K. C. Lim, J. Huang, R. F. Saidi, and C. L. Sears.** 1998. *Bacteroides fragilis* enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc. Natl. Acad. Sci. USA **95:**14979–14984.

304. **Wu, S., J. Powell, N. Mathioudakis, S. Kane, E. Fernandez, and C. L. Sears.** 2004. *Bacteroides fragilis* enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated protein kinases and a tyrosine kinase-regulated nuclear factor-κB pathway. Infect. Immun. **72:**5832–5839.

305. **Wu, S., J. Shin, G. Zhang, M. Cohen, A. Franco, and C. L. Sears.** 2006. The *Bacteroides fragilis* toxin binds to a specific intestinal epithelial cell receptor. Infect. Immun. **74:**5382–5390.

306. **Xu, J., M. K. Bjursell, J. Himrod, S. Deng, L. K. Carmichael, H. C. Chiang, L. V. Hooper, and J. I. Gordon.** 2003. A genomic view of the human-*Bacteroides thetaiotaomicron* symbiosis. Science **299:**2074–2076.

307. **Xu, J., H. C. Chiang, M. K. Bjursell, and J. I. Gordon.** 2004. Message from a human gut symbiont: sensitivity is a prerequisite for sharing. Trends Microbiol. **12:**21–28.

308. **Xu, J., and J. I. Gordon.** 2003. Honor thy symbionts. Proc. Natl. Acad. Sci. USA **100:**10452–10459.

309. **Yang, S. H., R. S. Yang, and C. L. Tsai.** 2001. Septic arthritis of the hip joint in cervical cancer patients after radiotherapy: three case reports. J. Orthop. Surg. (Hong Kong) **9:**41–45.

310. **Zaleznik, D. F., R. W. Finberg, M. E. Shapiro, A. B. Onderdonk, and D. L. Kasper.** 1985. A soluble suppressor T cell factor protects against experimental intraabdominal abscesses. J. Clin. Investig. **75:**1023–1027.